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ABSTRACT 
 
MARTIN THOMAS HALL: Prescription Drug Misuse Among Adolescents 
(Under the direction of Matthew Owen Howard) 
 
In spite of a growing body of knowledge of prescription drug misuse (PDM), several 
important gaps exist. This dissertation is comprised of three independent studies that 
advance knowledge of PDM among adolescents. Study 1 aims to provide a review of the 
epidemiology of adolescent PDM and offer a theoretical explanation of the problem using 
anthropological, cognitive-affective, and interpersonal theories of substance use. This 
theoretical discussion is important given that unlike illicit drugs, prescription drugs, when 
prescribed by health care professionals, are legal, pervasive, and often medically 
beneficial. The theories discussed in Study 1 highlight the unique qualities of PDM 
compared to use of illicit drugs. Study 2 aims to describe the prevalence and correlates of 
PDM and distinguish low- vs. high-frequency prescription drug misusers (PDMs) in a 
state population of youth in residential care for antisocial behavior (N = 723). This is the 
first known study to investigate the prevalence and correlates of PDM among youth in 
institutional care. Findings indicate that adolescents in residential care for antisocial 
behavior have high rates of PDM and comorbid psychiatric and behavioral problems. 
Youth served in institutional settings should be routinely screened and treated for PDM 
and co-occurring disorders. Study 3 used latent profile analysis (LPA) to identify 
subtypes of adolescent sedative/anxiolytic misusers (N = 247). LPA yielded three classes 
of sedative/anxiolytic misusers with significant heterogeneity across measures of 
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psychiatric and behavioral problems. Class 1 (59.1%) was comprised of youth with 
significantly lower levels of currently distressing psychiatric symptoms, fewer lifetime 
traumatic experiences, less problematic substance use histories, less frequent antisocial 
behavior, and less impulsivity than youth in Classes 2 and 3. Class 2 (11.3%) youth had 
high levels of currently distressing psychiatric symptoms and more frequent antisocial 
behavior compared to youth in Classes 1 and 3. Class 3 (29.5%) youth evidenced levels 
of psychiatric and behavioral problems that were intermediate to those of Class 1 and 2 
youth. Significant differences between classes were observed across a range of health, 
mental health, personality, and behavioral variables. Youth with comparatively high 
levels of anxiety and depression reported significantly more intensive sedative/anxiolytic 
misuse than their counterparts and may be at high risk for sedative/anxiolytic abuse and 
dependence.  
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CHAPTER 1 
PRESCRIPTION DRUG MISUSE AMONG ADOLESCENTS 
 
When you're stoned, you get paranoid and you have all those side effects and with hydrocodone 
you don't. You would be down and you wouldn't really care but you wouldn't have the side effects 
of paranoia or the munchies. You wouldn't have any of that but you would still be relaxed. You 
would be calm, you wouldn't have any pain, you  wouldn't be thinking about problems and you 
wouldn't be thinking about school. 
- Female undergraduate, explaining her preference for prescription opioids over 
marijuana (Quintero, Peterson, & Young, 2006, p. 918)      
   
Adolescence is a time of dramatic biological, cognitive, and social change 
(Berzonsky, 2000). The transition from childhood to adolescence is marked by increasing 
responsibility and independence, and is also a time when many adolescents initiate 
substance use (Johnston, O'Malley, Bachman, & Schulenberg, 2008). Adolescent 
substance use is associated with a number of undesirable outcomes such as delinquency 
(D’Amico, Edelen, Miles, & Morral, 2008); unprotected sexual intercourse and 
pregnancy (Stueve & O’Donnell, 2005); suicide risk (Cho, Hallfors, & Iritani, 2007); and 
lower academic achievement (Ellickson, Tucker, Klein, & Saner, 2004). Longitudinal 
research has shown that substance use during adolescence increases risk of adult 
criminality (Stenbacka & Stattin, 2007); lower educational attainment and unemployment 
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(Rohde et al., 2007); and adult substance abuse, dependence, and psychiatric disorders 
(Brook, Brook, Zhang, Cohen, & Whiteman, 2002).  
Whereas the prevalence of most illicit drug use has either plateaued or decreased 
in recent years, prescription drug misuse (PDM) has increased markedly (Colliver, 
Kroutil, Dai, & Gfroerer, 2006). A recent United Nations (U.N.) report speculated that 
rates of PDM might soon eclipse that of illicit drug use (U.N. International Narcotics 
Control Board, 2007). PDM occurs in all age categories, although misuse by adolescents 
is of particular concern because research has shown high rates of PDM among 
adolescents. For example, 1 in 10 adolescents reported misusing a prescription pain 
reliever in 2007 (Johnston et al., 2008). The two aims of this article are to (a) provide a 
review of the epidemiology of PDM among adolescents, and (b) offer a theoretical 
explanation of the problem. The unique qualities of prescription drugs (i.e., medically 
sanctioned, familiar, and often beneficial), as compared with illicit drugs, highlight the 
importance of a theoretical discussion on the issue of PDM.   
The primary focus of this article is on PDM among adolescents age 18 years and 
younger. This population was targeted because these adolescents generally still live at 
home. Though adopting 18 years of age as the upper bound of this study is arbitrary from 
a biological standpoint, it is defensible from a social and cultural standpoint. High-school 
graduation, which typically occurs around 18 years of age, represents an important social 
marker in U.S. culture, and the behaviors, including substance use, of those transitioning 
out of high school are influenced by increased independence, less parental oversight, and 
new social networks (Maggs, 1997; Schulenburg & Maggs, 2002). Studies have shown 
that regardless of whether adolescents attended college, those who have transitioned out 
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of high school reported more substance use than their peers who remained in high school 
(White, Labouvie, & Papadaratsakis, 2005). Because this article focuses on adolescents 
18 years and younger, the literature pertaining to late adolescence was not 
comprehensively reviewed, though a few studies with this population are cited for 
specific illustrative purposes. 
Defining Prescription Drug Misuse 
The literature makes frequent use of several terms to describe the misuse of 
prescription drugs. Commonly used terms are misuse, abuse, dependence, and addiction 
(Compton & Volkow, 2006); illicit use and medical use (McCabe et al., 2005); 
nonmedical use (Herman-Stahl, Krebs, Kroutil, & Heller, 2006); and extra-medical use 
(Degenhardt, Chiu, Sampson, Kessler, & Anthony, 2007). In addition, adolescents who 
misuse these drugs have coined colloquial terms such as pharming (Levine, 2007). This 
article uses prescription drug misuse (PDM) to refer to the four subtypes of misuse: (a) 
use of a prescription drug without a prescription (i.e., obtained illegally or not prescribed 
for the user) that is motivated by experimentation or the desire for euphoria; (b) use of a 
legitimately prescribed drug (i.e., prescribed for the user) for experimentation or 
achieving  euphoria; (c) use of a prescription drug without a prescription (i.e., obtained 
illegally or not prescribed for the user) that is motivated by a perceived physical or 
psychological need; and (d) use of a legitimately prescribed drug (i.e., prescribed for the 
user) in a way other than that intended by the prescriber to address the user’s perceived 
physical or psychological need (Boyd & McCabe, 2008). In addition to acknowledging 
divergent motivations for PDM, Boyd and McCabe’s (2008) definition captures the 
   4
continuum of PDM by accounting for infrequent or experimental use as well as more 
severe problems of abuse and dependence (American Psychiatric Association, 2000).  
Scope of the Problem 
Estimates  
 Adolescents and young adults are the largest demographic segment of prescription 
drug misusers (Substance Abuse and Mental Health Services Administration [SAMHSA], 
2009). Opioid (e.g., OxyContin, Vicodin) misuse is second only to marijuana use in 
prevalence among high-school seniors (12th grade) (Johnston et al., 2008). Rates reported 
in the 2007 National Survey on Drug Use and Health (NSDUH) were similar to MTF 
estimates; 9.7% of adolescents ages 12 to 17 reported lifetime prescription opioid misuse 
(Substance Abuse and Mental Health Services Administration, 2009b). Reports of PDM 
show the lifetime prevalence of PDM for this age group is second only to that of 18 to 25 
year olds, of whom 13% of males and 10% of females reported PDM. A sample of 1,086 
students in Grades 7 through 12 in one Michigan school district reported a 16% lifetime 
prevalence of PDM (McCabe, Boyd, & Young, 2007).  
 Rates of PDM vary by race and gender. Among 12th grade students nationally, 
12% of White students reported misusing a prescription opioid as compared to 3% of 
Black and 5% of Hispanic students (Johnston et al., 2008). Further, White students also 
reported higher misuse rates of prescription stimulants and CNS depressants, though 
differences among the racial groups were less extreme than for opioids. Early gender 
differences in PDM are seen in adolescent females who report slightly higher rates of 
PDM in the eighth grade than their male counterparts; however, by 12th grade, PDM 
among males either equals or surpasses that of their female counterparts (Johnston et al., 
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2008). These gender differences are consistent with those for several illicit drugs, and are 
hypothesized to result from earlier maturation among girls than boys.  
In 2006, 65,268 emergency department visits among persons 12 to 17 years of age 
involved the nonmedical use of pharmaceuticals (both prescription and nonprescription) 
(Substance Abuse and Mental Health Services Administration, 2008). This figure 
corresponds to an emergency department visit-rate of 256 visits per 100,000 youth. In 
2004, over 15,000 adolescent suicide attempts involved use of prescription drugs (Crane, 
2006). Over half of these drug-related suicide attempts involved use of a prescription pain 
medication, a higher percentage than for alcohol, marijuana, or other 
psychopharmacotherapeutic agents (e.g., antidepressants, antipsychotics, and 
anxiolytics).  
Correlation with Other Substance Use  
 Analysis of data obtained from the National Survey on Drug Use and Health 
(NSDUH) showed adolescents’ use of illicit drugs was the strongest correlate of 
prescription opioid misuse (Sung et al., 2005). The majority of adolescents who misused 
prescription opioids were polydrug users who shared demographic characteristics with 
adolescents who used only illicit drugs. Boyd, McCabe, and Teter (2006) reported similar 
findings in a survey of 1,017 adolescents in the Detroit metropolitan area. Boyd and 
colleagues found that, compared with other adolescents, youth who misused prescription 
opioids were eight times more likely to use illicit drugs and four times more likely to 
binge drink. 
 Similar findings have been reported for prescription stimulant (e.g., Ritalin) 
misuse. In a study assessing prescription stimulant misuse among middle- and high-
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school students, McCabe and associates (2004) found that adolescents who misused 
prescription stimulants were much more likely to report binge drinking and use of 
tobacco, marijuana, and ecstasy than nonusers. However, a study using NSDUH data 
showed that although an adolescent’s binge drinking did not predict prescription 
stimulant misuse, past use of marijuana and other illegal drugs was a predictor 
prescription stimulant misuse (Herman-Stahl et al., 2006).  
 Finally, McCabe and colleagues (2007) surveyed 1,086 secondary school students 
in the Detroit area about the use and misuse of four categories of prescription drugs: (a) 
sleeping medications, (b) sedative/anxiety medications, (c) stimulants, and (d) opioids. 
Findings revealed that for each of the four categories, misuse was associated with the use 
and abuse of other illicit drugs. McCabe, West, Morales, Cranford, and Boyd (2007) 
conducted one of the few studies investigating the effect of adolescent PDM on adult 
outcomes, and found PDM during early adolescence was a significant predictor of 
prescription drug abuse and dependence in adulthood. In summary, when adolescents 
who misuse prescription drugs are compared with peers who do not misuse these drugs, 
findings consistently demonstrate that PDM is a significant correlate of other substance 
use.   
Trends in Use by Specific Drug 
 The Monitoring the Future (MTF) survey is a continuing national survey of 
American youth and young adults’ behaviors, attitudes, and values (Johnston et al., 
2008). Since its inception in 1975, the MTF has collected data on participants’ 
prescription opioid use. Opium and codeine were the most prevalently used opioids in the 
early years of the study; while codeine remains one of the most frequently used opioids, it 
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has been surpassed by Vicodin (Johnston et al., 2008). After a gradual decline from the 
mid-1970s through the early 1990s, prescription opioid misuse increased sharply until the 
early 2000s. In 2002, when the MTF prescription opioid item was revised to include 
OxyContin, Vicodin, Percodan, and Dilaudid, prevalence estimates increased to the 
highest levels in MTF history. The use of prescription opioids has generally remained 
stable over the past five years. The use of Xanax, a benzodiazepine, which MTF began 
assessing in 2001, has overtaken Valium as the most frequently misused CNS depressant. 
In the early 2000s prescription opioids, tranquilizers, and stimulants stabilized and have 
remained so through 2007. 
Sources of Prescription Drugs for Misuse 
 Peers and family members play an important role in PDM. The 2007 MTF survey 
reported that between 55% and 59% (depending on the prescription drug class misused) 
of respondents who reported PDM obtained the drugs from a friend or relative with no 
payment involved (Johnston et al., 2008). Purchasing prescription drugs from friends or 
family members was reported by 38% to 43% of respondents, whereas stealing drugs 
from family or friends was mentioned by 17% to 27% of respondents. Adolescents also 
misuse drugs that have been prescribed for their own medical conditions; 40% of those 
who misused opioids reported they obtained the drugs using a prescription issued in their 
name.  
 Recent research suggests that studies of prescription drug diversion should 
distinguish friends and relatives as sources of drugs. One study designed to assess 
motivation for prescription opioid misuse among undergraduate college students showed 
that opioid misusers who received the prescription drug from their parents did not 
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significantly differ from nonusers on measures of problematic alcohol use or other 
substance use (McCabe, Cranford, Boyd, & Teter, 2007). However, misusers who 
obtained prescription drugs solely from peers were much more likely to have additional 
alcohol and substance use problems. Knowing whether misusers received drugs from 
friends or relatives (or both) would provide researchers and treatment providers with key 
information that is currently missing from many studies assessing sources of diverted 
prescription drugs. 
 The Internet does not appear to be a major source of prescription drugs misused 
by adolescents. Only 2% to 3% of adolescents who misused a prescription drug reported 
obtaining the drugs via the Internet (Johnston et al., 2008). Nevertheless, there has been a 
marked increase in the number of Web sites selling prescription drugs, of which more 
than 80% do not require a prescription (NCASA, 2007). The U.S. General Accounting 
Office (2004) conducted an investigation of Internet pharmacies and procured 68 samples 
of 11 different drugs, most without a prescription. These drugs included several opioids, 
and originated from U.S. pharmacies and pharmacies in Canada, Mexico, Pakistan, 
Spain, and Thailand.  
Problems Created for Legitimate Pain Patients 
 In addition to the risk PDM poses for individual misusers, PDM is increasingly 
creating hardships for patients with medical conditions that require powerful drugs. 
Zacny et al. (2003) asserted that an increasing number of physicians have opiophobia, 
which is hypervigilance regarding the prescribing of prescription opioids and 
unwarranted skepticism of patients with condition for which these drugs are indicated. In 
an effort not to be duped by drug-seeking patients, physicians may leave chronic pain 
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patients untreated or under-treated. In addition, patients who are prescribed powerful 
opioids may have difficulty getting the prescription filled because increasing numbers of 
pharmacies refuse to stock highly sought-after opioids due to fear of robbery (Conroy, 
2001). This situation is especially prevalent in impoverished, inner-city, and minority 
neighborhoods (Green, Ndao-Brumblay, West, & Washington, 2005; Morrison, 
Wallenstein, Natale, Senzel, & Huang, 2000). 
Review of Existing Research 
 Research on PDM among adolescents has several strengths. Prevalence estimates 
provided by the MTF (Johnston et al., 2008) and NSDUH (SAMHSA, 2008) surveys 
provide a vital service for both policy makers and treatment providers. Policy decisions, 
such as determining funding priorities, are guided by assessments of the nature and size 
of particular drug problems in the national population. Drugs of abuse tend to fluctuate in 
popularity, and trend analyses provided by MTF and NSDUH provide valuable, current 
information to substance use prevention experts, treatment providers, and researchers. 
However, MTF and NSDUH are limited in important ways in regard to PDM. For 
example, to assess opioid misuse MTF uses the item, “What narcotics other than heroin 
have you taken during the last year without a doctor's orders?” (Johnston et al., 2008). 
However, this item fails to capture three types of misusers: (a) an individual who 
deliberately overuses a legitimately prescribed drug (i.e., prescribed to that user); (b) an 
individual who obtains prescriptions from several doctors simultaneously to take 
excessive amounts of a drug but, who technically is under a doctor’s orders (also known 
as doctor shopping); and (c) an individual who uses a prescription drug beyond the time 
that it is necessary (e.g., using the drug months after surgery when there is no longer a 
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medical need). Thus, MTF fails to account for individuals who misuse prescription drugs 
they have been legally prescribed. As previously mentioned, 40% of adolescent opioid 
misusers identified by MTF reported obtaining the drug they misused via a prescription 
issued in their name (Johnston et al., 2008). Though the PDM items in the NSDUH 
questionnaire inquire about misuse of legally prescribed drugs, these items do not 
distinguish between medical and nonmedical PDM, making it impossible to discern the 
prevalence of each form of PDM.    
To accurately measure any phenomenon, a consistent and accurate definition of 
the construct is critical. In the study of PDM, some definitions have potentially blurred 
the distinctions between two types of misuse that differ in an important way. As 
previously discussed, research has shown that prescription opioid misuse is often 
motivated by a desire to relieve pain (Boyd, McCabe, Cranford, & Young, 2006; 
McCabe, Cranford, et al., 2007). Although this type of medical misuse is a cause for 
concern, it may constitute a fundamentally different behavior than the behaviors typically 
regarded as adolescent substance use. A comprehensive definition of PDM must include 
and distinguish between medical motives (e.g., pain relief, anxiety reduction) and 
motives related to experimentation, a desire for feelings of euphoria, and others.      
Finally, existing PDM research is limited by research design. Nearly all PDM 
research is cross-sectional in nature and, thus, limits the ability of researchers to 
determine causality or understand the temporal sequencing of problems that are related to 
PDM. For example, prescription drug misusers frequently use other illicit substances 
(McCabe et al., 2005; Sung et al., 2005); however, cross-sectional research makes it 
difficult to determine whether PDM precedes or follows use of other illicit drugs. 
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Similarly, cross-sectional research limits researchers’ ability to understand the course of 
PDM as the misuse transitions from experimental use to abuse and dependence. A second 
design problem associated with many PDM studies is sampling. Nearly all PDM research 
has taken place in schools or, to a lesser extent, in family homes. Such study designs omit 
incarcerated and institutionalized youth which are two segments of the adolescent 
population at high risk for substance use (Teplin, Abram, McClelland, Dulcan, & 
Mericle, 2002).  
Etiology of Prescription Drug Misuse: Theoretical Frameworks and Risk Factors 
 The following section offers an etiological explanation of PDM. First, literature 
from medical anthropology is used to provide a larger context of illness and treatment 
and how understandings of these issues relate to PDM. Following this discussion, 
cognitive-affective and interpersonal theories of substance use are applied to the problem.  
Anthropological Explanation of Prescription Drug Misuse 
The recent increase in PDM coincided with an increase in the numbers of 
prescriptions written. Between 1994 and 2005, the U.S. population grew 9% while the 
number of prescriptions increased by 71% (Kaiser Family Foundation, 2007), and the 
U.S. is by far the world’s largest consumer of opioids (International Narcotics Control 
Board, 2004). What accounts for these prescribing trends? This section of the paper 
discusses how PDM fits into the larger context of illness and treatment. 
To a varying extent, conceptualizations of illness are the product of culture. This 
is the concept that medical sociologists and anthropologists refer to when they describe 
medicalization, which was defined by Turner (2004) as the “social processes whereby 
social activities come under the control of medical institutions” (p. xiv). An increasing 
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range of human conditions and experiences have become medicalized, that is, moved 
from the social domain and treated as a medical problem. For example, Conrad (2007) 
has described the medicalization of the male aging process. A loss of testosterone, 
balding, and erectile dysfunction were historically seen as ordinary consequences of 
aging, whereas these occurrences are now regarded as medical problems with 
corresponding drug treatments. Although conditions are sometimes demedicalized (as 
was the case with homosexuality beginning in the 1970s), the general trend in 
contemporary society has been the expansion of medical jurisdiction (Conrad, 2007).  
A range of explanations may be offered in response to a particular human 
problem or condition. These explanations may be social, physical, mental, or spiritual in 
nature. For instance, in different cultures the causes of schizophrenia have been attributed 
to past-life trauma (Brazil; Moreira-Almeida & Neto, 2005); demon possession 
(Australia; Hartog & Gow, 2005); and interpersonal stress (Japan and Taiwan; 
Kurumatani et al., 2004). However, most people in industrialized countries tend to favor 
biomedical explanations of human problems. The perceived etiology of these problems 
then dictates the course of treatment. If an individual manifests symptoms associated with 
schizophrenia, the preferred treatment (e.g., medication, talk therapy, religious rituals) is 
dependent on the understanding of etiology. With biological pathology perceived as the 
primary source of problems in industrialized countries, the corresponding treatment is 
often medications. Thus, industrialized countries are marked by an ever-increasing range 
of experiences that are defined as illnesses or disorders and an ever-increasing range of 
pharmaceutical responses to these conditions. The result is a “pill-popping culture” 
(National Center on Addiction and Substance Abuse, 2005), exemplified by aggressive 
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marketing of drugs to health care providers and the increasing use of direct marketing of 
prescription products to consumers. Oldani (2004), a former pharmaceutical company 
representative turned anthropologist, stated, "We are not simply all just potential patients. 
Today, we are increasingly all potential consumers of pharmaceuticals…”(p. 345).  
The attraction to medicines lies not only in their promise of efficacy but also in 
their concreteness (van der Geest & Whyte, 1989). For the patient, a prescription for 
medicine represents a tangible response to their complaint. The patient's reported 
problems are thus validated by their doctor, and they are then entitled to the "privileges 
and roles reserved for the sick" (van der Geest, Whyte, & Hardon, 1996, p. 161). The 
benefits of medicines are not limited to the patient because the medical providers also 
benefit from the exchange. By writing a prescription, the provider has demonstrated his 
or her concern and effort to the patient. Both parties feel as though something has been 
"done." That is, the medical provider's need to give has been met as has the patient's need 
to receive (van der Geest et al., 1996). Figure 1.1 presents a graphic depiction of the 
relationship between the biomedical paradigm and prescription drug use, and summarizes 
the following points: (a) human conditions in industrialized countries are increasingly 
medicalized; (b) biological pathology is most often considered the source of problems; 
(c) biological pathology is primarily treated through medications; and (d) the transaction 
of medications from provider to patient provides perceived benefits to both parties, thus 
reinforcing their use. These four factors provide the context for the increasing utilization 
of prescription drugs, which has increased the market of available prescription drugs 
diverted for misuse.  
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Psychological and Sociological Theories of Adolescent Substance Use 
For reasons described in the preceding section, PDM is qualitatively different than 
other types of substance use. Therefore, theories commonly used to explain adolescent 
substance use may require new consideration. The two theories discussed in the 
following section, the theory of planned behavior (Ajzen, 1985) and social learning 
theory (Akers, 1992), have special relevance for understanding PDM. The focus on these 
two theories should not be interpreted as implying that other theories are unimportant to 
PDM. For example, intrapersonal theories of substance use, such as those emphasizing 
the implications of novelty-seeking personality traits for substance use (Cloninger, 1987), 
are important given that many adolescents who misuse prescription drugs are also 
polydrug users (Sung et al., 2005; McCabe, Boyd, et al., 2007). However, such theories 
are not considered here because they could be consistently applied across a number of 
drug categories, whereas the theory of planned behavior and social learning highlight the 
unique qualities of PDM. 
Cognitive-Affective Theories of Experimental Substance Use 
Cognitions are the central component of cognitive-affective theories of substance 
use. Personality traits, such as novelty seeking, would be mediated by an individual’s 
substance-specific expectations and beliefs. One particular example of a cognitive-
affective theory of substance use is the theory of planned behavior (TPB; Ajzen, 1985). 
TPB posits that behavioral beliefs, normative beliefs, and control beliefs form an 
individual’s intentions and actions (Ajzen, 1985). A behavioral belief represents an 
individual’s understanding of the outcomes of a particular behavior. These beliefs 
determine an individual’s attitude toward his or her behavior and whether the behavior 
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will have desirable or undesirable consequences. Behavioral beliefs influence and are 
influenced by an individual’s normative beliefs, which are an individual’s perceptions of 
how a behavior will be perceived by family, peers, and other important individuals. 
Normative beliefs determine subjective norms, the perceived pressure by key 
stakeholders about whether to engage in the behavior in question. Finally, control beliefs 
are an individual’s understanding of the attributes necessary to perform the behavior. 
Individuals are described as having high perceived behavioral control if they believe they 
possess the required knowledge, skills, or abilities to carry out a certain behavior. These 
three factors, attitude, subjective norms, and perceived behavioral control, combine to 
form an individual’s intention to engage in the behavior. The final construct preceding 
the successful completion of a behavior is actual behavioral control. Though intention 
may be strong, an individual’s execution of the behavior ultimately rests on possessing 
the necessary knowledge and skills.   
Several meta-analyses have provided support for the utility of TPB in predicting 
behavior across a range of domains (Armitage & Conner, 2001). In the context of 
substance use, TPB has been used to predict adolescent smoking behaviors (Maher & 
Rickwood, 1997) and alcohol consumption among early adolescents (Marcoux & Shope, 
1997) and college students (Hutching, Lac, & LaBrie, 2008). An application of TPB in 
the context of general adolescent substance use could be understood in the following 
way: potential substance users would (a) weigh the costs and benefits of engaging in use, 
(b) consider how such behavior would be viewed by key stakeholders such as peers and 
family, and (c) estimate their confidence about their ability to perform the identified 
behavior and achieve the desired outcome.  
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None of the existing research has specifically evaluated TPB in the context of 
PDM, though the theory seems to have face validity for the problem. Given the 
pervasiveness of beneficial prescription drug use, and that attitudes toward legitimate use 
in a medical context tend to be largely positive, it is reasonable that this tendency might 
favorably affect attitudes regarding misuse of these drugs. In addition, because these 
medications are known and trusted commodities, they are distinguished from other drugs 
of abuse that may seem more exotic and dangerous.  
Perhaps the TPB construct of control beliefs is most important with regard to 
PDM. Consider the example of two frequently abused opiates: heroin and Vicodin. In the 
case of heroin, even when it is assumed that adolescents hold positive attitudes toward 
heroin use (e.g., fostered increased social capital among peers) and considered its use 
common among peers (subjective norms), adolescents may still be reluctant to use the 
drug if they believe themselves to have inadequate knowledge or skills. For example, an 
adolescent might have questions about how to clean or procure syringes, how much 
heroin to inject, and where in the body should the drug be injected. These questions 
regarding heroin use may challenge an individual’s belief that he or she can use the drug 
successfully. Alternatively, the misuse of a prescription drug, such as Vicodin, is likely to 
present fewer challenges for an individual's control beliefs given the ease of use and 
availability of information. As with any other pill, Vicodin need only be swallowed, and 
unlike heroin, Vicodin comes with medically sanctioned dosage instructions. The 
threshold of knowledge and skill necessary to facilitate its use would be met by many 
adolescents. To illustrate this point, consider the following quote from a qualitative study 
of college-age prescription drug misusers (Quintero et al., 2006, p. 919): 
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To be honest, the reason I did prescription drugs was because it was an escape 
 from doing illegal drugs. Illegal drugs are a lot harder to me. Those seem to have 
 more of an effect. Are you going to overdose?...What's going to happen on this 
 drug? And with illegal drugs you don't know. With a prescription drug, a doctor's 
 not going to give you anything that's going to kill you, unless you take too much 
 of it.  
Criticisms of TPB are both empirical and theoretical in nature (Petraitis, Flay, & 
Miller, 1995). First, there is the issue of measurement. Many studies evaluating TPB are 
cross-sectional, making it difficult to differentiate whether beliefs and attitudes affect 
substance use; if substance use experience affects attitudes (i.e., positive experiences 
might increase favorable beliefs, attitudes, and self-efficacy regarding the drug); or 
whether beliefs, attitudes, and experiences affect each other in a reciprocal manner. 
Second, TPB stops short of explaining why some adolescents have preconceived positive 
expectations of substance use that precede their actual substance experience, as well as 
why some adolescents place great importance on social capital gained by using or not 
using substances.  
Social Learning Theories of Experimental Substance Use  
Social learning theory posits that an individual’s likelihood of substance use is 
influenced by what has been learned from group norms at the family level, community 
level, and culture at large (Akers, 1992). This theory bears some similarity to TPB in that 
it holds cognitions influence substance use behavior. However, social learning theory 
goes further than TPB in that social learning theory seeks to explain the origins of 
cognitions. Individuals' cognitions regarding substance use are based on observation, 
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imitation, and social reinforcement (Petraitis et al., 1995). For example, adolescents 
raised by substance-using parents or peers learn both how to use (e.g., how to mix 
alcoholic drinks or smoke marijuana) as well what can be expected (e.g., euphoric 
feelings or social capital).  
 This type of learning through observation also applies to prescription drugs. 
Indeed, this exposure is greater than other types of substances because 9 out of 10 
persons in the U.S. population have taken a prescription drug (National Center on 
Addiction and Substance Abuse, 2005), and prescriptions are now dispensed at a 
substantially greater rate than at any previous time in history (Zacny et al., 2003). The 
trend of increased prescription drug use is observable among adolescents as well. 
Between 1994 and 2001, prescriptions for adolescents increased 209% for stimulants and 
385% for anxiolytics and sedatives (Thomas, Conrad, Casler, & Goodman, 2006). 
Further evidence of adolescents’ increased exposure to prescription drugs is provided by 
a Michigan study in which 45% of students surveyed in a large school district reported 
having been prescribed opioids (Boyd et al., 2007). The pervasiveness of prescription 
drug use means that adolescents have ample opportunity to observe appropriate use in the 
context of daily living. The vast majority of these observations will consist of a neutral or 
positive outcome; therefore, what is learned through these observations is that 
prescription drugs are widespread, effective, and safe. Evidence in support of this 
argument can be found in the MTF study (Johnston et al., 2008). Findings from the 2007 
MTF survey indicated that 28% of 12th grade students perceived high risk related to 
experimental use of CNS depressants as compared with 58% for heroin; 48% for 
phencyclidine (PCP); 45% for cocaine; and 37% for d-lysergic acid diethylamide (LSD). 
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As previously discussed, normative beliefs about the safe and appropriate use of 
prescription drugs may also affect normative beliefs about their misuse. An adolescent 
who has seen a family member or peer safely and appropriately use a prescription opioid 
may have difficulty differentiating that use from his or her own misuse. 
Increased legitimate prescription drug use as well as increased PDM may also 
influence perceptions of misuse. For example, a recent study showed that college students 
overestimated prescription opioid and stimulant misuse to a significantly greater degree 
than they did for marijuana use (McCabe, 2008). McCabe (2008) described a possible 
cyclical relationship; perceived norms might predict PDM and subsequent actual PDM 
then affects perceived norms.  
The theory of social learning is not without challenges (Petraitis et al., 1995). 
First, studies investigating social learning theory must address the time-order issue as it 
relates to the impact of peer substance use. For example, does peer involvement affect 
substance use, or is there a self-selection process whereby adolescents at risk for 
substance use cluster together? Similarly, social learning theory does not address an 
adolescent's motivation for associating with substance-using peers and, therefore, fails to 
address factors which facilitate entry into substance-using peer groups. 
Summary and Analysis 
 This article has reviewed theories representing anthropological, 
cognitive/affective, and interpersonal constructs in the context of adolescent PDM. 
Though not yet tested in the specific context of PDM, the usefulness of TPB and social 
learning in understanding other types of adolescent substance use provides face validity 
for this particular problem. The legality and pervasiveness of prescription drugs make 
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TBP and social learning theories particularly applicable to understanding misuse. 
Although both theories are limited in their explanations of substance use, when 
considered in tandem and in the context of medicalization, they provide a promising 
explanation of adolescent PDM. The three primary cognitions outlined in TPB, 
behavioral beliefs, normative beliefs, and control beliefs, could be influenced by social 
learning theory (i.e., an adolescent's cognitions, the origins of which are unaccounted for 
in TPB, may result from what is learned in families, among peers, and within the larger 
social context). Similarly, although limited, the TPB explanation of why adolescents 
associate with substance-using peers (i.e., because they hold favorable cognitions of 
substance use) complements social learning theory.      
 Notably, these theories are considered primarily to understand and explain PDM 
for reasons other than medical need. As discussed, research among adolescents and 
young adults has shown that PDM often results from perceived need. One study of high 
school students found that 69% of those who reported opioid misuse did so solely to 
relieve pain (Boyd et al., 2006). Similarly, pain relief was the most frequently cited 
motive among a sample of college-age prescription opioid misusers (McCabe, Cranford, 
et al., 2007). Although TPB and social learning theory would likely still be informative in 
understanding this form of PDM, their application would require a modification from that 
previously described.  
Implications and Conclusions 
 PDM is relatively common among adolescents. For this reason, substance use 
prevention programs should include content on PDM. One measurable outcome of such 
efforts would be changing cognitions adolescents have about risks associated with PDM. 
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Youth who misuse prescription drugs are likely to use a number of other substances 
(Sung et al., 2005), and those who progress from experimental substance use to problems 
of abuse and dependence with one particular substance are likely to be susceptible to 
problems with other substances (Young, Rhee, Stallings, Corley, & Hewitt, 2006). These 
points suggest that treatments should not be specific to PDM but should instead target 
broader problems of abuse, dependence, and related conditions. For example, if providers 
increase the use of buprenorphine for adolescents dependent on prescription opioids, that 
treatment should be offered in conjunction with evidence-based psychosocial treatments.  
 Given the dangers associated with PDM, medical practitioners, human services 
providers, and school staff should ensure that the adolescents they serve are routinely 
screened for PDM using a formal screening instrument. Clinical impressions, although 
valuable, are not sufficient; one recent study reported that pediatricians guided only by 
clinical impression failed to detect 76 of 86 (88%) cases of adolescent substance abuse or 
dependence (Wilson, Sherritt, Gates, & Knight, 2004). Improvements in screening and 
monitoring of patients, both adolescent and adult, are also a critical part of reducing 
prescription drug diversion. Part of this effort must occur in medical practices as well as 
in the training providers receive in medical and nursing schools. Studies have shown that 
medical training programs underemphasize the challenges of prescribing controlled 
substances and identifying diversion (National Center on Addiction and Substance 
Abuse, 2005). When PDM is identified, adolescents should be informed about the 
associated risks and referred for substance use treatment services.   
  
 
CHAPTER 2 
PRESCRIPTION DRUG MISUSE AMONG ANTISOCIAL YOUTH 
 
Most epidemiological research examining adolescent prescription drug misuse 
(PDM1) has been conducted in schools, or to a lesser degree, in homes. School-based 
studies, such as the Monitoring the Future (MTF) (Johnston, O'Malley, Bachman, & 
Schulenberg, 2008) survey, omit populations of truant, dropout, homeless, and 
institutionalized youth. Neither MTF nor National Survey on Drug Use and Health 
(NSDUH) (Substance Abuse and Mental Health Services Administration, 2009b) include 
institutionalized youth, an adolescent subpopulation at presumably high risk for PDM 
(Howard, Balster, Cottler, Wu, & Vaughn, 2008; Teplin, Abram, McClelland, Dulcan, & 
Mericle, 2002). This study is the first, to our knowledge, to investigate the prevalence and 
correlates of PDM among youth in institutional care. Specific aims of the study were to 
describe the prevalence and correlates of PDM and to characterize low vs. high frequency 
PDMs in a state population of youth in residential care for antisocial behavior.  
                                                 
1Chapters 2 and 3 use the acronym PDM to signify nonmedical prescription drug misuse 
(i.e., any non-prescribed use of a prescription drug), which is distinguished from medical 
prescription drug misuse (i.e., the deliberate misuse of a legally prescribed prescription 
drug by the person for whom the prescription drug was written). 
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Although nonmedical PDM is a longstanding problem in the U.S., its significance 
as a public health issue has increased dramatically in recent years. Whereas use of most 
illicit drugs has plateaued or decreased since the early 1990s, PDM has increased 
markedly (Colliver, Kroutil, Dai, & Gfroerer, 2006). Adolescents and young adults are 
among the largest demographic subpopulations of nonmedical prescription drug misusers 
(PDMs) (Substance Abuse and Mental Health Services Administration, 2009). More than 
one-in-eleven (9.2%) 12th grade students  reported prescription opioid misuse in the 2007 
MTF national survey; misuse of prescription opioids was second only to marijuana use in 
the magnitude of its past-year prevalence of use (Johnston, O'Malley, Bachman, & 
Schulenberg, 2008). Prevalence estimates of the 2007 NSDUH were similar to MTF 
estimates; 9.7% of adolescents ages 12 to 17 reported prescription opioid misuse 
(Substance Abuse and Mental Health Services Administration, 2009b).  
 An analysis of NSDUH data found illicit drug use to be the strongest correlate of 
prescription opioid misuse among adolescents (Sung, Richter, Vaughan, Johnson, & 
Thom, 2005). Similar findings were reported in a survey of 1017 adolescents residing in 
the Detroit metropolitan area (Boyd, McCabe, & Teter, 2006); prescription opioid 
misusers were eight and four times more likely, respectively, to use other illicit drugs and 
to binge drink than nonmisusers of prescription opioids. Misuse of non-opioid 
prescription drugs, such as sedatives and anxiolytics, is also associated with illicit drug 
use and substance-related problems (McCabe, Boyd, & Young, 2007). In summary, 
recent findings suggest that PDM is prevalent in the general U.S. adolescent population 
and that PDMs are significantly more likely than non-PDMs to use illicit drugs.   
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One of few studies to examine effects of adolescent PDM on adult outcomes 
found that early adolescent PDM was a significant predictor of PDM and 
abuse/dependence on prescription drugs in adulthood (McCabe, West, Morales, Cranford, 
& Boyd, 2007). Though there is limited research on the long-term consequences of 
adolescent PDM, adolescent substance use in general is associated with adverse 
outcomes, including lower academic achievement (Ellickson, Tucker, Klein, & Saner, 
2004), delinquency (D’Amico, Edelen, Miles, & Morral, 2008), unprotected sexual 
intercourse and unplanned pregnancy (Stueve & O’Donnell, 2005), and suicide risk (Cho, 
Hallfors, & Iritani, 2007). Longitudinal research suggests that adolescent substance use 
also increases risk for criminality (Stenbacka & Stattin, 2007), unemployment (Rohde et 
al., 2007), substance use disorders and psychiatric dysfunction (Brook, Brook, Zhang, 
Cohen, & Whiteman, 2002) in adulthood.  
Methods 
 For a full description of the study sample, including recruitment and sampling 
methods and detailed information regarding study measures, see Howard, Balster, 
Cottler, Wu, and Vaughn (2008). 
Study Sample 
The study sample was drawn from the 32 residential rehabilitation facilities of the 
Missouri Division of Youth Services (DYS), the legal guardian of youth ages 13-17 who 
are in residential care for antisocial behavior. The 723 youth who were interviewed 
constituted 97.7% of DYS residents at the time interviews were conducted. Thus, the 
present study is virtually a census of the population of DYS residents at the time the 
study was undertaken and a large, representative sample of DYS annual residents. The 
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DYS client population is representative of youth in residential care for antisocial behavior 
nationally with regard to age, gender and number of state youth in residential care per 
100,000 adolescents (Sickmund, 2002). 
Interviews were completed in 2003 and were 60-to-90 minutes in duration. 
Fifteen graduate students conducted the interviews after completing an intensive 1-day 
training session. An interview editor and the project principal investigator were on-site at 
each facility as youth were interviewed to minimize interviewer errors. Interviews were 
conducted in private areas where confidentiality was assured. Youth signed informed 
assent forms and were provided with $10.00 for completing the interview. All youth were 
provided a description of their privacy rights, a copy of a Washington University 
brochure, “Your Privacy Matters…,” and a copy of the informed assent agreement. The 
informed assent form and interview protocol provided residents with detailed information 
about the study, their rights as human subjects, and the name and contact telephone 
number for a non-study or university-affiliated advocate whom they could call for more 
information about the study. DYS was the legal guardian of all youth and provided 
formal permission for youths to participate in the study. The informed consent and study 
protocols were approved by the Missouri DYS IRB, Washington University Human 
Studies Committee IRB, and federal Office of Human Research Protection, and was 
granted a Certificate of Confidentiality by the National Institute on Drug Abuse.  
Measures 
 Demographic factors. Gender, age (years), self-reported racial status (i.e., African 
American, White, Latino, Biracial, Other), grade (current or last completed), family 
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receipt of public assistance (yes or no), and urbanicity of family residence (i.e., urban, 
suburban, small town, rural) were recorded for each youth.   
 Medical history. Respondents indicated whether (yes or no) they had ever 
experienced each of eight medical conditions (e.g., a head injury that produced 
unconsciousness; were diagnosed by a psychiatrist or other physician with a mental 
disorder).    
 Prescription drug misuse. Items assessing PDM were adapted from the 
Diagnostic Interview Schedule for DSM-IV (DIS-IV) (Robins, Helzer, Croughan, & 
Ratcliff, 1981). Respondents were asked four questions about their use of prescription 
drugs that were not prescribed for them: 1) Have you ever used “other opiates” (e.g., 
methadone, morphine, OxyContin, Demerol, Vicodin)?; 2) Have you ever used 
barbiturates (e.g., Downers, Yellows, Reds, Blues, or Soapers)?; 3) Have you ever used 
tranquilizers (e.g., Valium, Librium, Xanax, Serax)?; and 4) Have you ever used 
prescription drugs without a prescription [if youth responded “yes” to this item, they were 
asked to name the prescription drugs they had misused and their responses were recorded 
verbatim]? Any youth reporting nonprescribed use of “other opiates,” barbiturates, or 
tranquilizers was classified as a lifetime prescription drug misuser. Youth who answered 
affirmatively to the fourth question listed above and who reported nonprescribed use of 
one or more prescription opioids, barbiturates, or tranquilizers were also classified as 
lifetime PDMs. For each of the four prescription drug misuse questions, youth reported 
whether or not they had ever used the specific class of prescription drugs (yes or no) and 
the total number of days in their lifetime during which they had misused that class of 
prescription drugs (i.e., < 5, 5-10, 11-99,  ≥ 100). 
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Other substance use. Use of 14 additional categories of psychoactive substances 
was assessed: inhalants, heroin, cocaine/crack, speed, marijuana, hallucinogens, malt 
liquor, other alcohol, ecstasy (MDMA), GHB/GBL, cigarettes, cigars, oral tobacco, and 
PCP. Youth reported whether or not they had ever used each drug (yes or no) and the 
number of days of use of that drug in their lifetime (< 5, 5-10, 11-99, ≥ 100). Each youth 
was also characterized in terms of the total number of drug types they had used (range 1-
14). 
 Substance-related problems. Lifetime substance-related problems were assessed 
with the 8-item Alcohol/Drug Use Scale of the Massachusetts Youth Screening 
Instrument—2nd Version (MAYSI-2) (Grisso & Barnum, 2000). Youth responded “yes” 
or “no” to questions assessing maladaptive substance-related behaviors (e.g., whether 
they had ever been so drunk or high they couldn’t remember what happened). Scores 
could range from 0 to 8 (α = .83).   
 Suicidal ideation. Youth completed the 5-item MAYSI-2 Suicide Ideation scale (α 
= .91). Youth responded “yes” or “no” to questions asking whether or not they had ever 
wished they were dead, felt like life was not worth living, or felt like hurting themselves.  
 Lifetime trauma. All respondents completed a 4-item Traumatic Experiences scale 
adapted from the MAYSI-2. Youth responded “yes” or “no” to items assessing history of 
specific traumatic experiences (e.g., have you ever seen someone severely injured or 
killed (in person-not in the movies or on TV?) (α =.69).   
Current psychiatric symptoms. Respondents completed the Brief Symptom 
Inventory (BSI), consisting of 53 items assessing the extent to which youth were 
“bothered or disturbed” (0 = not at all; 4 = extremely) by a variety of thoughts or feelings 
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“over the last 7 days including today” (Derogatis, 1993). The BSI yields a global index of 
overall current psychiatric distress (possible range = 0 to 212, α = .96) and scores for 9 
primary symptom dimensions: Somatization, Obsessive-Compulsive, Interpersonal 
Sensitivity, Depression, Anxiety, Hostility, Phobic Anxiety, Paranoid Ideation, and 
Psychoticism (α’s = .70-.83). 
  Antisocial traits. Youth completed the Antisocial Process Screening Device 
(APSD) (Vitacco, Rogers, & Neumann, 2003), a 20-item scale assessing features of 
juvenile psychopathy. Respondents were asked to indicate to what extent each statement 
was true of them (0 = not at all true, 1 = sometimes true, 2 = definitely true). The ASPD 
total score as well as the Impulsivity (α =.67) and Narcissism (α = .75) subscales were 
used in this study. Study participants also completed the 56-item Psychopathic 
Personality Inventory Short-Version (PPI-SV) (Lilienfeld & Andrews, 1996). Youth were 
asked to decide to what extent each of the personality characteristics described in each 
statement were false or true as applied to them (1 = false, 2 = mostly false, 3 = mostly 
true, 4 = true). The PPI-SV yields a total score (possible range = 56 to 224, α = .76) and 
eight subscales: Machiavellian Egocentricity, Social Potency, Coldheartedness, Carefree 
Nonplanfulness, Fearlessness, Blame Externalization, Impulsive Nonconformity, and 
Stress Immunity (α’ s = .55-.73). 
 Delinquent behavior. The Self-Report of Delinquency (SRD) (Elliott, Huizinga, 
& Menard, 1989) was used to assess how many times in the year before they entered 
institutional care youth engaged in 7 nonviolent and 10 violent crimes. Responses could 
range from 0 (never) to 8 (2-3 times a day) for each item. Total SRD scale scores could 
range from 0 to 136, while the ranges of possible scores were 0-56 and 0-80 for the 
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nonviolent and violent offense subscales, respectively. Using the same response format, 
youth completed a 4-item Victimization Index (possible range = 0 to 32, α =.76) to assess 
frequency of personal experiences of criminal victimization (e.g., “were hit by someone 
trying to hurt you”) in the year prior to institutionalization. Youth also reported the ages 
at which they first committed a criminal offense and had contact with police, 
respectively. 
Data Analysis 
 The participation rate for this study was high and there were few missing data; 
most items were missing less than 1% of responses. In instances where case deletion 
results in the loss of a very small proportion of the overall sample, it is an appropriate 
approach to handling missing data (Schafer & Graham, 2002) and was utilized in 
reported analyses. Bivariate and adjusted comparisons of lifetime PDMs and non-PDMs 
were conducted using χ2 and logistic regression for categorical variables and t-tests and 
multiple regression for continuous variables.  Homogeneity of variance assumptions were 
tested and degrees of freedom adjusted as appropriate. Effect sizes were computed and 
presented as either odds ratios or Cohen’s d (Cohen et al., 2003). Multiple logistic 
regression analyses were used to identify correlates of PDM and to differentiate low (1 to 
10 lifetime occasions of use, N = 143) vs. high (≥11 lifetime occasions of use, N = 162) 
frequency PDMs.  
Results 
 Sample characteristics. Demographic features of the sample are presented in 
Table 2.1. The sample was composed largely of boys; nearly two-thirds were 15 or 16 
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years old. Subjects were ethnically diverse and a substantial minority (40.3%) reported 
that their families currently received public assistance.  
 Prevalence of PDM. Overall, 314 (43.4%) youth reported lifetime PDM. 
Prescription opioids, tranquilizers, and barbiturates were misused by 33.7%, 32.0%, and 
11.2% of the sample, respectively. PDMs often misused multiple classes of prescription 
drugs. For example, 72.3% of tranquilizer misusers also misused prescription opioids. Of 
all PDMs, 40.1% misused a prescription drug from only one class, 43.0% misused drugs 
from two classes, and 16.9% misused drugs from all three prescription drug classes. 
Thus, a majority of PDMs were users of multiple classes of prescription drugs.   
 Bivariate comparisons of PDMs and non-PDMs. Space limitations preclude a 
complete presentation and discussion of bivariate comparisons of PDMs and non-PDMs; 
thus, only results of significant bivariate contrasts of PDMs and non-PDMs are presented 
in Table 2.2. However, nonsignificant findings not reported in Table 2.2 are available by 
request from the first author. PDM was significantly more prevalent among girls (54.3%) 
than boys (41.8%), but differences by gender across the three classes of prescription 
drugs with regard to mean age at first use or number of lifetime days of use were not 
significant. PDMs did not differ from non-PDMs with regard to proportions with families 
receiving welfare, but did differ significantly from non-PDMs across measures of age, 
gender, race, and urbanicity of family residence. PDMs were older and more likely to be 
girls, White, and reside in a small town than non-PDMs.  
 A significantly larger percentage of PDMs than non-PDMs sustained a head 
injury that resulted in loss of consciousness. Significantly more PDMs than non-PDMs 
had been diagnosed by a psychiatrist or other physician with a psychiatric disorder, and 
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PDMs evidenced significantly greater severity of current psychiatric symptoms on the 
BSI Global Severity Index and on eight of nine BSI subscales than non-PDMs. PDMs 
evidenced significantly greater antisociality on the APSD total score measure and 
impulsivity subscale compared to non-PDMs. Similarly, PDMs had significantly higher 
scores on the PPI total score measure of psychopathy as well as six of eight PPI 
subscales.  
PDMs were significantly more likely than non-PDMs to have used all categories 
of psychoactive substances (complete findings available on request). Of variables 
examined in bivariate contrasts, mean lifetime number of drug types used evidenced the 
largest effect (d = 1.76). In addition, PDMs reported more lifetime days of use than non-
PDMs for marijuana [t (622) = -9.7, p < .001], LSD [t (163) = -2.3, p < .05], malt liquor 
[t (302) = -5.9, p < .001], beer, wine, liquor [t (585) = -11.1, p < .001], cigarettes [t (239) 
= 6.8, p < .001], and cigars [t (289) = -4.4, p < .001]. PDMs had significantly higher 
scores than non-PDMs on the MAYSI-2 subscales assessing lifetime number of alcohol 
and drug-related problems, suicide ideation, and traumatic experiences.  
PDMs did not differ significantly from non-PDMs in the number of past-year 
violent crimes they committed, but did commit significantly more numerous past-year 
property crimes than non-PDMs. Also, the mean ages at commission of first crime and 
first contact with police were significantly younger for PDMs than non-PDMs. 
Multiple logistic regression analysis identifying correlates of PDM. Variables 
were included in the logistic regression model identifying correlates of PDM based on 
prior findings in the PDM and general substance use literatures and results of bivariate 
analyses. A correlation matrix of continuous independent variables was examined for 
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evidence of multicollinearity, and none of the obtained Pearson Product-Moment 
correlations exceeded r = 0.5. The following independent variables were simultaneously 
entered into the multiple logistic regression model: gender (male = 1, female = 0), race 
(African American [reference group], White, Latino/Latina,  Other), age (years), 
urbanicity of family residence (small town = 1, other areas = 0), history of mental illness 
(0 = no, 1 = yes), lifetime inhalant use (0 = no, 1 = yes), lifetime cocaine/crack use (0 = 
no, 1 = yes), lifetime marijuana use (0 = no, 1 = yes), lifetime LSD use (0 = no, 1 = yes), 
MAYSI-2 Substance-related problems scale, BSI-Global Severity Index, PPI-Carefree 
Nonplanfulness subscale, PPI-Fearlessness subscale, SRD-Property Crime subscale, 
APSD-Impulsivity subscale, MAYSI-2 Suicidal ideation subscale, and MAYSI-2 
Traumatic Experiences subscale. 
Model coefficients, statistical tests, odds ratios, and 95% confidence intervals for 
odds ratios are presented in Table 2.3. Seven covariates were significant at p < .05. 
Compared to African Americans, youth identifying as White or other ethnicities were 
approximately three times as likely to report PDM. A one-year increase in age increased 
the odds of PDM by a factor of 1.6. The highest odds ratios for the model were observed 
for substance use variables. Marijuana users were nine times (OR = 9.2) more likely than 
non-marijuana users to report PDM, whereas prior experiences with inhalants (OR = 2.8) 
and LSD (OR = 4.3), and an impulsive temperament (OR = 1.1), were also significant 
risk factors for PDM. 
 Bivariate comparisons of low- and high-frequency PDMs. Detailed results of 
bivariate comparisons of low- and high-frequency PDMs, including statistical test results 
and effect sizes, are available on request from the first author. Low- and high-frequency 
   33
PDMs did not differ on any demographic variables other than racial status; African 
Americans were more likely to be low-frequency PDMs compared to youth of other 
races. High-frequency PDMs were significantly more likely than low-frequency PDMs to 
report having experienced a head injury that caused unconsciousness and to have been 
diagnosed with a psychiatric disorder. High-frequency PDMs also had significantly 
higher scores than low-frequency PDMs on the PPI total score measure, and PPI 
subscales assessing impulsive nonconformity and carefree nonplanfulness. Scores on the 
APSD impulsivity subscale, MAYSI-2 suicidal ideation and traumatic experiences scales, 
and Victimization Index were also significantly higher for high-frequency than low-
frequency PDMs. High-frequency PDMs also had significantly higher scores on seven of 
nine BSI scales, committed significantly more past-year violent and property crimes, and 
evidenced an earlier onset of criminal behavior than low-frequency PDMs. 
 Multiple logistic regression analysis discriminating high- vs. low-frequency 
PDMs.  Variables were included in the multiple logistic regression analysis 
distinguishing high- vs. low-frequency PDMs (low = 0, high = 1) if they were 
significantly associated with frequency of PDM in bivariate contrasts. If two variables 
were highly correlated and conceptually similar, one was excluded from the analysis. The 
following variables were simultaneously entered into the logistic regression model: race 
(African American [reference group], White, Latino/Latina, Other), history of head injury 
with loss of consciousness, BSI-Somatization and Anxiety subscales, MAYSI-2 
Substance-Related Problems scale, APSD-Impulsivity subscale, PPI-Carefree 
Nonplanfulness subscale, SRD-Violent Offending and Property Crime subscales, 
victimization index, age at first crime, and MAYSI-2 Suicidal Ideation scale.   
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 Results of the logistic regression analysis distinguishing high versus low-
frequency PDMs are presented in Table 2.4. Greater temperamental impulsivity and more 
numerous lifetime substance-related problems were characteristic of high-frequency 
PDM. Extent of past-year criminal victimization approached statistical significance (p = 
.08).   
Discussion 
 The lifetime prevalence of PDM in this state population of institutionalized youth 
was 43.4%; this PDM prevalence estimate is considerably higher than comparable 
estimates reported for the general U.S. adolescent population. Prevalence estimates for 
lifetime prescription opioid and tranquilizer misuse in this sample were nearly three times 
the lifetime use prevalence rates reported for adolescents in the Monitoring the Future 
study (Johnston, O'Malley, Bachman, & Schulenberg, 2008). Further, a majority of youth 
reporting PDM had misused multiple classes of prescription drugs. 
 More than half (54.3%) of the girls interviewed in this study reported PDM, 
compared to 41.8% of boys. In 8th grade, girls in the general population report slightly 
higher rates of PDM than boys; however, by 12th grade, PDM among boys equals or 
surpasses that of girls (Johnston, O'Malley, Bachman, & Schulenberg, 2008). Thus, it is 
possible that the higher rate of PDM among girls in this study is attributable to the 
average age of the sample. The scarcity of girls in this sample older than 16 prevented 
comparisons of younger and older youth. Future research should investigate PDM among 
older youth to discern whether the gender differences observed among antisocial youth in 
this study dissipate over time.  
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 PDM was most prevalent among White (55.5%) and Latino (53.5%) youth. 
Although “only” 18.5% of African American youth reported PDM, this rate is notably 
higher than that reported for African American youth participating in 2007 Monitoring 
the Future survey (Johnston, O'Malley, Bachman, & Schulenberg, 2008). Rates of 
lifetime prescription opioid misuse for 12th grade students participating in the 2007 MTF 
were 17% for Whites, 4% for African Americans, and 7% for Latinos. In this study of 
younger respondents, prescription opioid misuse was reported by 46% of Whites, 9% of 
African Americans and 43% of Latinos. Thus, differences between racial groups have 
been observed in the general U.S. adolescent population and in this study of high risk 
youth, although in absolute terms the rates are much higher among the high-risk youth 
studied in this investigation. 
 Youth from small towns were disproportionately more likely to report PDM. This 
finding is consistent with prior research reporting higher prevalence rates of Vicodin and 
OxyContin use in nonmetropolitan areas (McCabe, Boyd, & Teter, 2005). Prescription 
opioid misuse in the general U.S. adolescent population has leveled off in recent years, 
although the rate of misuse among adolescents living in nonmetropolitan areas has 
continued to rise (Johnston, O'Malley, Bachman, & Schulenberg, 2008). Despite the 
increasing prevalence of PDM among urban and suburban youth, PDM remains a form of 
substance use that is disproportionally located in nonmetropolitan areas. 
 PDMs evidenced a number of serious medical, psychiatric, and behavioral 
problems, including more varied, frequent, and problematic psychoactive substance use, 
higher levels of distressing psychiatric symptoms, and significantly greater likelihood of 
diagnosis with mental illness. Traumatic life experiences, more extensive histories of 
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criminal victimization, and higher levels of suicidal ideation were also found 
disproportionately in PDMs. These findings raise the possibility that some PDM results 
from adolescents’ efforts to self-medicate dysphoric or anxious mood states. Previous 
research has distinguished subgroups of PDMs based on motives for use (Boyd, McCabe, 
Cranford, & Young, 2006). Some nonmedical misusers of prescription drugs are 
motivated to self-medicate symptoms of psychiatric (e.g., anxiety) or medical (e.g., pain) 
problems, whereas others may be motivated by curiosity about drug effects or the desire 
to achieve euphoria. The high rates of PDM among youth in residential care may reflect 
efforts to self-medicate symptoms of anxiety and depression, a greater propensity to seek 
out euphoric experiences, or both. Future PDM research should examine reasons for use 
as prevention and intervention efforts in this area will likely require such information if 
they are to be optimally effective.  
 High-frequency PDMs represented an especially troubled group of adolescents. In 
comparison with low-frequency PDMs, high-frequency PDMs were more impulsive, 
committed more property and violent crimes, initiated criminal careers at an earlier 
average age, and were more likely to report a history of head injury, criminal 
victimization, traumatic life events, psychiatric disorder, and distressing psychiatric 
symptoms.   
 Consideration of motives for PDM (Boyd, McCabe, Cranford, & Young, 2006; 
McCabe, Boyd, & Teter, 2009) may also provide a useful context for understanding 
frequency of PDM. High-frequency PDMs reported higher levels of physical and 
psychiatric problems that could lead to misuse of prescription opioids, benzodiazepines, 
and barbiturates. At the same time, impulsivity and substance-related problems were also 
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predictive of high-frequency PDM, suggesting that prescription drugs may represent just 
another type of substance abuse for these youth. Given that most PDMs report different 
motives for different episodes of misuse (McCabe, Boyd, & Teter, 2009), it seems likely 
that youth in this study may also have had varied intentions. These findings illustrate the 
importance of developing a more nuanced understanding of the etiology of PDM among 
various subpopulations of adolescents including those in different clinical and service 
settings. 
 Most research assessing the prevalence, correlates, and predictors of PDM has 
been conducted in schools and household settings. A key strength of this study is that it is 
among, if not the first to examine the epidemiology of PDM in a sample of high-risk 
youth in residential care. Other study strengths include the high participation rate and 
large sample size. This research has two limitations: (1) the study did not assess 
prescription stimulant misuse, and (2) PDM questions asked respondents whether they 
had used a prescription drug when it was not prescribed for them. This item structure may 
not have captured youth who misused their own legally prescribed prescription drugs. 
These two limitations (and the self-report nature of the drug use measures) may have 
resulted in an underestimation of the overall prevalence of PDM in this sample; that said, 
the prevalence rates identified were among the highest yet reported for any adolescent 
subpopulation and underscore the seriousness of the current PDM epidemic in the U.S.  
  
 
CHAPTER 3 
SUBTYPES OF ADOLESCENT SEDATIVE/ANXIOLYTIC MISUSERS:  
A LATENT PROFILE ANALYSIS 
 
1. Introduction 
 Prescription drug misuse (PDM1) is prevalent in the U.S. An estimated 6.4 million 
persons ages 12 and older reported past-month PDM in 2005 (Lessenger & Feinberg, 
2008). Adolescents and young adults are the largest demographic subpopulation of 
nonmedical prescription drug misusers (PDMs) (Substance Abuse and Mental Health 
Services Administration, 2009). Sedative/anxiolytic misuse is among the most prevalent 
and consequential forms of adolescent PDM. In national surveys, 9.3% and 9.5% of 12th 
grade students report lifetime sedative and anxiolytic misuse, respectively (Johnston, 
O’Malley, Bachman, & Schulenberg, 2008). Increases in the prevalence of 
sedative/anxiolytic misuse may reflect increases in the number of prescriptions written 
for drugs in these classes. Between 1994 and 2001, there was a 385% increase in the 
number of sedative/anxiolytic prescriptions written for adolescents (Thomas, Conrad, 
Casler, & Goodman, 2006). Diversion of these agents is common and is a key factor in 
the growing misuse of drugs in these classes (Boyd, McCabe, Cranford, and Young, 
2007; Johnston, O’Malley, Bachman, & Schulenberg, 2008).  
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 Misuse of prescription sedatives or anxiolytics is highly correlated with illicit 
substance use among adolescents (Boyd, McCabe, & Teter, 2006; McCabe, Boyd, & 
Young, 2007; Sung et al., 2005). One of few studies to investigate effects of adolescent 
PDM on adult outcomes found that PDM in early adolescence was a significant predictor 
of PDM and dependence on prescription drugs in adulthood (McCabe, West, Morales, 
Cranford, & Boyd, 2007). Sedative/anxiolytic misuse can contribute to impaired 
judgment, impulsive or disinhibited behavior, substance dependence, and adverse 
medical outcomes such as respiratory depression and arrest (particularly in combination 
with alcohol) (National Institute on Drug Abuse, 2005). Long-term anxiolytic use may 
result in cognitive deficits that persist even when the drugs are discontinued (Stewart, 
2005). Given the notable prevalence and seriously adverse consequences of prescription 
sedative/anxiolytic misuse, this study focused specifically on adolescent 
sedative/anxiolytic misusers.  
Previous surveys of PDMs have identified categories of misusers based on 
motive(s) for use, route(s) of administration, and co-ingestion with alcohol (McCabe, 
Boyd, & Teter, 2009). Using these characteristics, three categories of misusers were 
established: self-treatment misusers who misuse prescription drugs to treat perceived 
medical or psychiatric problems, recreational misusers who misuse prescription drugs for 
experimental reasons or to achieve euphoria, and mixed motive misusers who report self-
treatment and recreational motives for use on different occasions (McCabe, Boyd, & 
Teter, 2009). These subtypes of PDMs may differ in important ways. Compared to self-
treatment opioid misusers, adolescent recreational and mixed-motive opioid misusers 
reported higher levels of marijuana use, alcohol abuse, binge drinking, and substance-
   40
related problems (Boyd, McCabe, Cranford, & Young, 2006). Importantly, differences 
among subtypes vary depending on the prescription drug class misused. A study of PDM 
in an undergraduate sample showed that self-treatment misusers of hypnotics, 
sedatives/anxiolytics, and prescription stimulants reported more substance use and 
substance-related problems than nonusers of these agents (McCabe, Boyd, & Teter, 
2009). Self-treating prescription opioid misusers, however, did not differ significantly 
from nonusers of prescription opioids with regard to substance use and substance-related 
problems. These findings suggest that there may be important, but largely unrecognized, 
differences between misusers of different classes of prescription drugs.  
 The primary aim of the research reported herein was to use latent profile analysis 
(LPA) to develop an empirically-based taxonomy of adolescent sedative/anxiolytic 
misusers. Prior empirical work in this area is limited to a small number of studies that 
differ from the present study in important ways. For example, in contrast to the school-
based sample used by Boyd, McCabe, Cranford, and Young (2006), the sample used for 
these analyses consisted of youth in residential treatment for antisocial behavior. This 
group is at high-risk for substance use and co-morbid psychiatric disorders (Howard, 
Balster, Cottler, Wu, & Vaughn, 2008; Teplin, Abram, McClelland, Dulcan, & Mericle, 
2002), though no prior studies, to our knowledge, have specifically investigated PDM 
among delinquent or institutionalized youth populations. A second notable difference 
between previous studies of PDM subtypes and the present study involves the types of 
measures and analytic strategy employed. This study used a wide range of psychiatric, 
health, personality, and behavioral measures in conjunction with a person-centered 
analytic approach to identify classes of adolescent sedative/anxiolytic misusers. Given 
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these and other differences, this effort was exploratory in nature and the number and 
nature of potential PDM classes were not specified a priori.  
Identifying subtypes of PDMs could be useful in future efforts to match specific 
prevention and treatment interventions to adolescent PDMs with different constellations 
of attributes. Malleable risk factors may differ among subtypes of adolescent PDMs; for 
example, prevention efforts for self-treatment misusers may emphasize mental health 
treatment, whereas prevention efforts for recreational misusers may resemble general 
substance use prevention activities. Additionally, a better understanding of subtypes of 
sedative/anxiolytic misusers may enable earlier identification of youth at risk for 
sedative/anxiolytic misuse, abuse, and dependence. Some youth may become dependent 
after using sedatives/anxiolytics primarily for self-treatment purposes, whereas for others, 
sedative/anxiolytic misuse may reflect a general substance use problem.  
2. Methods 
2.1 Sample and procedures  
 For a full description of the parent study from which the current sample is drawn, 
including recruitment and sampling methods, as well as detailed information about all 
measures, see Howard et al., 2008. The present study sample of sedative/anxiolytic 
misusers (N = 247) was drawn from a larger (N = 723) 2003 survey of youth in 
residential care for antisocial behavior in Missouri. The survey completed interviews with 
97.7% of youth residing at the 32 residential facilities comprising the Missouri Division 
of Youth Services treatment system, making it a virtual census of the population of youth 
in state care for antisocial conduct at that time.   
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Fifteen graduate students conducted project interviews after completing an 
intensive 1-day training session. An interview editor and the project principal investigator 
were on-site at each facility as youth were interviewed to minimize interviewer errors. 
Interviews were 60-to-90 minutes in duration and were conducted in private areas where 
confidentiality was assured. Youth signed informed assent forms and were provided with 
$10.00 for completing the interview. All youth were provided a description of their 
privacy rights, a copy of a Washington University brochure, “Your Privacy Matters…,” 
and a copy of the informed assent agreement. The informed assent form and interview 
protocol provided residents with detailed information about the study, their rights as 
human subjects, and the name and contact telephone number for a non-study or 
university-affiliated advocate whom they could call for more information about the study. 
The Missouri Division of Youth Services was the legal guardian of all youth and 
provided formal permission for residents to participate in the study. The informed 
consent and study protocols were approved by the Missouri DYS IRB, Washington 
University Human Studies Committee IRB, and federal Office of Human Research 
Protection, and were granted a Certificate of Confidentiality by the National Institute on 
Drug Abuse.  
2.2 Measurement of sedative/anxiolytic misuse 
 Items assessing sedative/anxiolytic misuse were adapted from the Diagnostic 
Interview Schedule for DSM-IV (DIS-IV) (Robins, Helzer, Croughan, & Ratcliff, 1981). 
Respondents were asked three questions about their use of sedatives and anxiolytics that 
were not prescribed for them: 1) Have you ever used barbiturates (e.g., Downers, 
Yellows, Reds, Blues, or Soapers)?; 2) Have you ever used tranquilizers (e.g., Valium, 
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Librium, Xanax, Serax)?; and 3) Have you ever used prescription drugs without a 
prescription? [If youth responded “yes” to this query, they were then asked to name the 
specific prescription drug(s) they had used and their responses were recorded verbatim]. 
Any youth reporting nonprescribed barbiturate or tranquilizer use was classified as a 
lifetime nonmedical prescription drug misuser. Additionally, youth who answered 
affirmatively to the third question listed above and who reported nonprescribed lifetime 
use of one or more prescription sedatives or anxiolytics were also classified as lifetime 
nonmedical prescription drug misuser. Overall, prescription anxiolytics and sedatives 
were misused by 32.0% and 11.2% of the larger sample, respectively. The majority of 
youth who reported sedative misuse also reported anxiolytic misuse; of the 80 sedative 
misusers, 64 (80%) reported anxiolytic misuse, indicating considerable overlap among 
the two categories of PDM. Combined, these items resulted in a total of 247 lifetime 
sedative/anxiolytic misusers. 
2.3 Analysis  
Latent profile analysis (LPA) was conducted with Mplus 4.2 (Muthen & Muthen, 
2006) and used to identify subtypes of adolescent PDMs. LPA is an extension of latent 
class analysis (LCA) and is similar to other latent variable approaches such as factor 
analysis; all are methods of data reduction used to identify subgroups within a larger 
population (Muthen & Muthen, 2000). Whereas LCA uses only categorical variables to 
identify homogenous subgroups, LPA can also use continuous measures. Notably, 
LCA/LPA analyses classify individuals based on observed indicator variables. In LCA 
and LPA, an individual’s observed scores are considered indicators of a latent variable. 
As such, respondents’ observed data cluster with those of other respondents in the same 
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latent class and differ from those in other latent classes. Model building is conducted in a 
stepwise manner until an optimal model fit is achieved. As probability-based methods, 
LCA and LPA possess advantages over more rigid grouping methods such as cluster 
analysis, which rely on measures of distance between observations. As such, LCA and 
LPA allow researchers to know the probability of assignment to k latent classes for each 
respondent.   
 Although there is not a single measure of model fit for latent variable modeling, 
the Bayesian Information Criterion (BIC) is a commonly used and reliable measure 
(Nylund, Asparouhov, & Muthen, 2007). Lower BIC values represent better model fit. A 
second measure of model fit is the Lo-Mendell-Rubin (L-M-R) likelihood-ratio test 
statistic (Nylund et al., 2007). The L-M-R provides a significance test comparing a more 
complex model to a model with one less class. In this comparison, a nonsignificant L-M-
R indicates that the more parsimonious model cannot be rejected. A third criterion for 
model fit is latent class probability (Muthen & Muthen, 2000). The latent class 
probability statistic represents the likelihood that subjects are consistently assigned to a 
particular class. Higher values represent better model fit; for example, a class probability 
value of .99 would indicate that a respondent’s assignment to a particular class was 
consistent 99% of the time. Finally, entropy values range from zero to one and are 
estimated for each model. Values closer to one represent more accurate assignment to 
subgroups. The BIC value, L-M-R test, latent class probability estimates, and entropy 
were used to assess model fit. Further considerations relevant to model selection were the 
conceptual interpretability and parsimony of derived models. 
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2.3.1 Measures used for latent profile modeling. The nine variables presented in 
Table 3.1 were the indicators used for LPA modeling. Indicators one through four 
consisted of scores on the following Brief Symptom Inventory (BSI) subscales: 
Somatization, Depression, Anxiety, and Phobic Anxiety (Derogatis, 1993). For these 
subscales, youth were asked to what extent they were “bothered or disturbed” by a 
variety of thoughts or feelings “over the last 7 days including today.” Subscale items 
assessed psychiatric distress experienced in relation to each symptom domain. Symptoms 
of anxiety and depression may be associated with sedative/anxiolytic misuse as a form of 
self-treatment (Becker, Fiellin, & Desai, 2007). Youth who use these drugs 
experimentally, however, may report comparatively low scores on these scale items. 
Indicator five was the Traumatic Experiences scale of the Massachusetts Youth Screening 
Instrument—2nd Version (MAYSI-2; Grisso & Barnum, 2000). Traumatic experiences are 
included as an indicator variable because they reliably predict anxiety, depression, and 
other psychiatric problems (Copeland, Keeler, Angold, & Costello, 2007), which could 
lead to self-treatment with sedative/anxiolytic drugs. Indicators six and seven, the 
MAYSI-2 Alcohol/Drug Use scale and lifetime number of drug classes used, were 
selected because, unlike self-treatment misusers, recreational misusers have been found 
to have significantly higher levels of illicit substance use and substance-related problems 
(Boyd, McCabe, Cranford, & Young, 2006; McCabe, Boyd, & Teter, 2009). Because 
previous studies with youth in this sample have shown high rates of comorbid substance 
use and psychiatric conditions (Howard et al., 2008), two additional indicators were 
included in an effort to further distinguish distinct classes of sedative/anxiolytic misusers. 
Indicator eight, the Self-Report of Delinquency (SRD; Elliott, Huizinga, & Menard, 
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1989), assessed how many times youth engaged in 7 nonviolent and 10 violent crimes in 
the year before they entered residential care. The final indicator was the Impulsivity 
subscale of the Antisocial Process Screening Device (APSD; Vitacco, Rogers, & 
Neumann, 2003). Delinquency and impulsivity are significantly correlated with substance 
use (D’Amico, Edelen, Miles, & Morral, 2008; Dawe & Loxton, 2004) and may represent 
additional domains that usefully discriminate between existing subtypes of 
sedative/anxiolytic misusers. 
 2.3.2 Measures used to compare classes. Classes identified using LPA were 
compared across demographic, health, mental health, substance use, personality, and 
criminological profiling measures. Demographic variables included gender, age (years), 
self-reported racial status (i.e., African American, White, Latino, Biracial, Other), grade 
(current or last completed), family receipt of public assistance (yes or no), and urbanicity 
of family residence (i.e., urban, suburban, small town, rural). Eight medical conditions 
(e.g., head injury producing unconsciousness; mental illness diagnosed by a psychiatrist 
or other physician) were assessed by asking respondents whether (yes or no) they had 
ever experienced each condition.  
 Frequency of substance use was assessed by asking youth the number of days of 
use in their lifetime for each of 15 categories of psychoactive substances (< 5, 5-10, 11-
99, and ≥ 100). Classes were also compared using the 5-item MAYSI-2 Suicide Ideation 
scale (α = .91), assessing thoughts and feelings about suicide (e.g., “have you ever wished 
you were dead”). Current (i.e., past week) psychiatric symptoms were compared among 
classes using five BSI symptom subscales: Obsessive-Compulsive, Interpersonal 
Sensitivity, Hostility, Paranoid Ideation, and Psychoticism (α’s = .70-.83). 
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  Antisocial traits were assessed among the classes using the 56-item Psychopathic 
Personality Inventory Short-Version (PPI-SV; Lilienfeld and Andrews, 1996). Youth 
were asked to decide to what extent each of the personality characteristics described in 
each statement were false or true as applied to them (1 = false, 2 = mostly false, 3 = 
mostly true, 4 = true). The PPI-SV yields a total score (possible range = 56 to 224, α = 
.76) and eight subscales: Machiavellian Egocentricity (e.g., “I am more important than 
most people”), Social Potency (e.g., “I am a good conversationalist”), Coldheartedness 
(e.g., “It bothers me greatly when I see someone crying”; reverse scored), Carefree 
Nonplanfulness (e.g., “I generally prefer to act first and think later”), Fearlessness (e.g., 
“I occasionally do something dangerous because someone has dared me to do it”), Blame 
Externalization (e.g., “A lot of people in my life have tried to stab me in the back”), 
Impulsive Nonconformity (e.g., “I’ve always considered myself to be something of a 
rebel”), and Stress Immunity (e.g., “I’m the kind of person who gets stressed out pretty 
easily”; reverse scored) (α’ s = .55-.73). Study participants also completed the 7-item 
APSD Narcissism subscale (α = .75).  
 Classes were also compared using a 4-item Victimization Index (possible range = 
0 to 32, α =.76) to assess frequency of personal experiences of criminal victimization 
(e.g., “were hit by someone trying to hurt you”) in the year prior to entering residential 
rehabilitation. Responses could range from 0 (never) to 8 (2-3 times a day) for each item. 
Youth also reported the ages at which they first committed a criminal offense and had 
contact with police. 
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3. Results 
3.1 Characteristics of adolescent sedative/anxiolytic misusers  
The predominantly male (83.8%) sample had a mean age of 15.8 years (S.D. = 
1.1). Most youth were White (70.0%), followed by African American (13.8%), Latino 
(5.3%), and other ethnicities (10.9%). A majority of youth reported residing in 
nonmetropolitan areas prior to entering residential treatment (53.8% small town/rural vs. 
46.2% urban/suburban). 
3.2 Latent profile analysis 
 LPA models with two, three, and four classes were analyzed. Table 3.2 presents 
fit indices for the three models assessed. Using the criteria previously described, the 
three-class model was selected as the best fit to the data. The three-class model had a 
smaller BIC value than the two-class model and a statistically significant L-M-R test, 
indicating that the addition of a third class improved model fit compared to the two-class 
solution. Though the four-class solution had a lower BIC value and higher entropy score 
than the three-class model, it had slightly lower average class probability than the three-
class model. Additionally, the four-class model yielded one class (N = 9) that was too 
small to use in subsequent analyses of differences among latent classes. Finally, the L-M-
R test of the four-class solution was nonsignificant, indicating that the addition of a 
fourth class did not significantly improve model fit over the three-class solution.   
 Table 3.3 provides mean comparisons across the nine indicator variables for the 
three derived latent classes. ANOVAs and Tamhane post-hoc tests reveal clear 
differences among the three classes. Class 1 was the largest (59.1%, n = 146) group, 
consisting of youth with comparatively low levels of psychiatric distress, traumatic 
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experiences, substance use, antisocial behavior, and temperamental impulsivity. Class 2 
was the smallest (11.3%, n = 28) group and was comprised of youth distinguished 
primarily by high levels of distress due to somatization, depression, anxiety, and phobic 
anxiety symptoms in comparison with Classes 1 and 3. Class 3 (29.5%, n = 73) consisted 
of youth with moderately elevated scores across the nine indicator variables. Though 
Classes 2 and 3 did not differ significantly on five of nine indicator variables, all three 
classes were clearly distinguished by scores on measures assessing current distress due to 
psychiatric symptoms. Figure 3.1 presents standardized means of the three classes across 
each indicator variable. 
3.3 Comparisons of adolescent sedative/anxiolytic misuser latent classes 
 The three latent classes of sedative/anxiolytic misusers were compared across 
demographic, physical/mental health, substance use, personality, and criminological 
measures. Results of these analyses are presented in Table 3.4. Due to space limitations, 
only significant findings are presented. Non-significant findings are described in the 
footnote to Table 3.4 and are available from the first author by request. There were no 
significant group differences across demographic variables, though girls (25.0%), Latinos 
(17.9%), and youth residing in urban areas (46.4%) were overrepresented in Class 2.  
 Class 1 youth reported a history of fewer health and mental health problems than 
youth in Classes 2 and 3. Over half of youth in Class 2 reported a history of head injury 
producing unconsciousness, a significantly higher proportion than reported by youth in 
Classes 1 and 3. Youth in Class 3 were more likely to have been diagnosed with a mental 
illness than members of Class 1, whereas youth in Class 2 were more likely to report a 
history of hearing voices compared with members of Class 1. Each of the three classes 
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differed significantly on the MAYSI-2 suicidal ideation scale and the five BSI subscales 
used for profile analysis. Class 1 and Class 2 youth evidenced the lowest and highest 
psychiatric severity, respectively. Substantial differences were observed between Classes 
1 and 2 for suicidal ideation (Cohen’s d = 1.4), obsessive-compulsive symptoms (d = 
3.4), interpersonal sensitivity (d = 2.2), hostility (d = 1.9), paranoid ideation (d = 2.5), 
and psychoticism (d = 2.8).  
Frequency of substance use differed significantly among classes for several drug 
use categories. Class 1 consistently reported the lower frequency of use for each of 15 
psychoactive substances, whereas no significant differences in frequency of use were 
observed between Classes 2 and 3. Notably, frequency of lifetime sedative/anxiolytic 
misuse was significantly greater among youth in Classes 2 and 3 compared to youth in 
Class 1.     
Members of Classes 2 and 3 evidenced significantly greater antisocial personality 
traits on the APSD narcissism subscale compared to members of Class 1. Classes 
demonstrated varied findings in regard to psychopathy. Class 3 had significantly higher 
PPI Total scores than Class 1 (d = .38), but did not differ significantly from Class 2. 
Class 1 reported higher scores on social potency, coldheartedness, and stress immunity 
subscales compared with Classes 2 and 3. Class 2 reported significantly lower levels of 
social potency than Classes 1 and 3; otherwise, Class 2 and Class 3 did not differ across 
PPI subscales, and both classes reported significantly higher scores on Machiavellian 
egocentricity, carefree nonplanfulness, blame externalization, and impulsive 
nonconformity than Class 1. Compared to Class 1, Classes 2 and 3 evidenced higher 
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levels of past-year criminal victimization, and no differences were observed among 
classes with regard to age of onset of criminal offending and contact with police.  
4. Discussion 
 LPA of adolescent sedative/anxiolytic misusers identified three distinct groups of 
youth. These findings contribute to an emerging literature documenting clinically 
relevant heterogeneity among adolescent PDMs. By assessing the mental health status of 
sedative/anxiolytic misusers, this work complements previous research categorizing 
PDMs based on motive for use, route of administration, and co-ingestion with alcohol 
(Boyd, McCabe, Cranford, & Young, 2006; McCabe, Boyd, & Teter, 2009). This study 
also demonstrates that misusers can be meaningfully classified using measures of 
psychiatric symptoms, substance use problems, antisocial behavior, and temperament.   
 Youth in Class 1, who were the majority (59.1%) of sedative/anxiolytic misusers 
in this study, reported comparatively low levels of psychiatric problems, substance use 
and related problems, traumatic experiences, antisocial behavior, and impulsivity. Youth 
in this class used sedatives/anxiolytics, as well as other psychoactive substances, less 
frequently than did members of Classes 2 and 3. Given these youths’ comparatively low 
scores on BSI measures assessing anxiety, depression, and related problems, they may 
lack a need or motive to use sedatives/anxiolytics for self-treatment. Neither does this 
class comport with McCabe and colleagues (2009) recreational subtype, given their 
relatively low levels of substance use and related problems compared to other classes 
identified in this study. Instead, Class 1 youth seem to represent a group of youth whose 
sedative/anxiolytic misuse was primarily limited to experimentation and who evidenced 
low levels of psychopathology and behavior disturbances. 
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 Class 2 (11.3%) and Class 3 (29.5%) were smaller in size and reported similar 
scores across four-of-nine indicator variables. However, Classes 2 and 3 differed 
substantially with regard to severity of current psychiatric symptoms, and to a lesser 
degree, antisocial behavior. Class 2 exhibited significantly higher scores than other 
classes across the four BSI indicators used to derive the LPA classes, as well as the five 
remaining BSI subscales used for comparative analyses. Given their high levels of 
anxiety and other distressing psychiatric symptoms, members of Class 2 may use 
sedatives/anxiolytics for self-treatment purposes. The self-treatment subtype has been 
shown to be more common among girls (McCabe, Boyd, & Teter, 2009), and the group 
with the highest proportion of girls in this study was Class 2. However, Class 2 was also 
more impulsive and had higher rates of substance use and related problems than Class 1, 
suggesting they were more likely to have used sedatives/anxiolytics for recreational 
purposes. Class 3 was comprised of moderately troubled misusers. Compared to Class 1, 
Class 3 reported higher rates of psychiatric symptoms across all BSI measures, 
suggesting an elevated need to use sedatives/anxiolytics for self-treatment purposes. 
Similar to Class 2, however, Class 3 also had higher rates of impulsivity and substance 
use than Class 1. This group may represent a mixed-motive subtype. It is notable that 
frequency of sedative/anxiolytic misuse was highest among Classes 2 and 3, groups that 
also reported the highest rates of psychiatric symptoms for which sedatives/anxiolytics 
would be medically indicated. In sum, depressive and anxious symptomatology in 
adolescence may lead to self-treatment misuse of prescription sedatives/anxiolytics and, 
when conjoined with antisocial attitudes and behaviors, may lead to mixed motive 
prescription drug misuse.  
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 These findings are consistent with previous nationally representative studies of 
comorbid sedative/anxiolytic misuse and distressing psychiatric symptoms. Anxiety, 
social anxiety, panic, agoraphobia, and depression were found to be significantly 
correlated with sedative/anxiolytic misuse in an analysis of data from the National Survey 
on Drug Use and Health (Becker, Fiellin, & Desai, 2007). Similarly, Goodwin and Hasin 
(2002) identified major depression, suicidal ideation, agoraphobia, and antisocial 
personality disorder as significant correlates of nonmedical prescription sedative misuse 
among respondents to the National Comorbidity Survey. These studies highlight the 
importance of research on subtypes of PDMs. If the subtypes identified in this study can 
be extended to general population studies, significant differences between PDMs and 
nonmisusers across levels of psychiatric symptoms may result from the elevated rates of 
these symptoms by Class 2 and 3 misusers. Put another way, our findings suggest that 
influential subtypes of sedative/anxiolytic misusers may exaggerate overall differences 
between misusers and nonmisusers in regard to level of psychiatric symptoms. In this 
study, Class 1 misusers, who we described as likely experimental misusers, reported 
comparatively low levels of psychiatric symptoms and comprised 59.1% of all adolescent 
sedative/anxiolytic misusers.    
 Recent research has demonstrated that universal preventive interventions 
administered in middle school reduce PDM in late adolescence and early-adulthood 
(Spoth, Trudeau, Shin, & Redmond, 2008). Such efforts would likely benefit the majority 
of youth at risk of PDM (e.g., the low-severity youth in Class 1). For youth whose 
profiles more closely match Classes 2 and 3, however, the effectiveness of universal 
preventive interventions may be limited. For these youth, whose PDM may be driven by 
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the desire to medicate distressing psychiatric symptoms, alternative or supplementary 
preventive interventions may need to be developed. Additionally, these findings highlight 
the importance of integrated substance use and mental health treatment (Mueser, 
Noordsy, Drake, & Fox, 2003). Despite growing consensus that integrated treatment is 
the optimal approach for individuals with co-occurring disorders, research suggests that it 
is still a rarity in practice (Harris & Edlund, 2005).   
 In conclusion, three distinct classes of adolescent sedative/anxiolytic misusers 
were identified. When compared to the self-treatment, recreational, and mixed subtypes 
of PDMs described by McCabe and colleagues (2009), similarities and differences are 
evident. Differences could result from the types of measures used (i.e., motives, co-
ingestion vs. mental health status), samples studied (normative, school-based vs. high-
risk, residential treatment), or analysis procedures (variable-centered approach vs. 
person-centered approach) employed. However, taken together, these studies indicate that 
PDM is a multifaceted behavior undertaken by diverse youth with varying motives. 
Intervention targets for PDMs should consist of universal preventive interventions for 
substance use as well as increased attention to mental health treatment.   
 Measures used in this study were self-report in nature and possibly were subject 
to various response and recall biases. However, self-report studies are normative in 
substance use research and research has documented their validity except in 
circumstances where strong incentives operate to bias responding (Harrison, Martin, 
Enev, & Harrington, 2007). A second limitation is the cross-sectional design of the study, 
which does not allow for an assessment of the temporal ordering of reported associations. 
Third, the structure of the sedative/anxiolytic questions, which asked respondents 
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whether they had used drugs from these classes that were not prescribed for them, may 
not have captured youth who exclusively misused their own prescription drugs (i.e., 
medical prescription drug misuse). This limitation could have led to an underestimation 
of the number of PDMs. Though given the high rates of sedative (11.2%) and anxiolytic 
(32.0%) misuse reported in the larger sample of the parent study, we believe the risk of 
undetected PDM to be low. Fourth, the small size of Class 2 (N = 28) may have limited 
power to detect differences among subgroups in the study. Finally, this study used a high-
risk sample and elected to focus only on sedative/anxiolytic misuse. The derived subtypes 
may not be generalizeable to community-based samples or misusers of other categories of 
prescription drugs. Although findings from this study share important commonalities 
with prior work using school-based populations (Boyd, McCabe, Cranford, & Young, 
2006), future research should use latent variable approaches to investigate subtypes of 
prescription opioid and stimulant misusers in high-risk and general population samples of 
youth. Longitudinal studies of different classes of adolescent nonmedical PDMs using 
latent growth curve modeling might provide useful information regarding the differential 
long-term outcomes of youth in these subgroups. Despite these limitations, this study is 
the first to examine the epidemiology of sedative/anxiolytic misuse among delinquent 
youth and to identify subtypes of adolescent PDMs using LPA.  
  
 
CHAPTER 4 
OVERALL SUMMARY AND CONCLUSIONS 
 
 The three papers that comprise this dissertation advance the knowledge of PDM 
among adolescents. Study 1 provided a theoretical explanation of PDM among youth, 
Study 2 described the prevalence and correlates of PDM among a high-risk and 
vulnerable sample of adolescents, and Study 3 identified three distinct subtypes of 
sedative/anxiolytic misusers. Though the dissertation consists of three independent 
studies, this section of the paper will briefly interpret the empirical findings from Studies 
2 and 3 in light of the theoretical issues discussed in Study 1. 
 The theories described in Study 1 explain PDM from cultural (i.e., the 
anthropological perspective), relational (i.e., social learning theory), and cognitive (i.e., 
theory of planned behavior) perspectives. To summarize, the expansion of medical 
jurisdiction, and the resultant increase in prescription drug treatments, provides abundant 
opportunities for adolescents to observe and engage in prescription drug use. The 
familiarity of prescription drugs, as well as perceptions of their safety, may influence the 
attitudes, subjective norms, and control beliefs youth have about PDM. 
 These theories may be useful in explaining the high rates of PDM reported by 
youth in Study 2. Given that family history is one the most reliable predictors of 
substance use problems (Merikangas et al., 1998), it is reasonable that substance use 
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behaviors were modeled by the parents of many of the youth in this study. Though 
genetic influences exert a large effect on problems of abuse and dependence, 
environmental influences have been shown to be most influential in predicting substance 
use initiation (Fowler et al., 2007; Rhee et al., 2003). Similarly, the youth profiled in 
Study 2 are highly likely to have been exposed to substance use through peer 
relationships, also among the strongest risk factors for substance use (Hawkins, Catalano, 
& Miller, 1992).  
 Study 3 identified subtypes of sedative/anxiolytic misusers based primarily on 
psychiatric profiles. The theories described in Study 1 appear relevant regardless of 
frequency of PDM or PDM subtype; however, frequency and subtype may require the 
adaptation of certain theoretical constructs. In regard to TPB, for example, self-treatment, 
recreational, and mixed-motive misusers all likely hold favorable attitudes about PDM, 
though the behavioral beliefs that precipitate these attitudes may differ by subtype. In the 
context of self-treatment, the behavioral belief that fosters favorable attitudes toward 
PDM may involve the expected efficacy of a prescription drug to alleviate a perceived 
problem. For recreational misusers, however, the behavioral belief leading to favorable 
attitudes toward PDM may result from expectations of euphoria. Mixed-motive misusers 
may hold both these types of behavioral beliefs simultaneously. Similarly, low-and high-
frequency misusers may have different beliefs about what is to be gained from PDM, 
though both groups ultimately hold favorable attitudes toward the behavior. Another TPB 
construct, normative beliefs, also may differ by frequency group and subtype. For some 
youth, self-treatment PDM may be subjectively normative, whereas recreational PDM 
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may remain non-normative. Other theoretical constructs, such as control beliefs, could 
most likely be applied consistently across PDM subtypes.  
 There is an important implication of this discussion for prevention interventions 
and treatments that might rely on a TPB model to address PDM (presuming that such 
interventions target behavioral beliefs and subjective norms). If the behavioral beliefs that 
undergird favorable attitudes about PDM vary by subtype, then TPB-based interventions 
must allow for multiple behavioral beliefs. Thus, TPB-based interventions for PDM 
should include content focused on behavioral beliefs associated with both self-treatment 
(e.g., expectations of reduced symptoms) and recreational misuse (e.g., expectations of 
euphoria). Similarly, normative beliefs should be understood as potentially varying by 
subtype. It may be normative in some families for members to share prescription drugs 
when there is a perceived physical or psychiatric need, though only in such cases. In 
other families, prescription drugs may be shared for multiple reasons. Both experiences 
may foster normative beliefs about PDM, and should be addressed in the context of TPB-
based interventions.  
 In summary, these findings argue for a nuanced understanding of PDM that is 
sometimes missing from more general discussions of adolescent substance use. The 
theories described herein provide fairly broad applicability in explaining adolescent 
PDM, though only by being flexible enough to accommodate important differences 
among PDMs. Prevention interventions, particularly those informed by TPB, may benefit 
from giving full consideration to the heterogeneity found in adolescent PDMs.       
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Biomedical Paradigm
Medicalization of Human Conditions
Biological Pathology is Source of 
Problems
Medications Treat Pathology
Social Exchange Reinforces Use of  
Medications 
 
Figure 1.1 Anthropological Model of Prescription Drug Use 
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Table 2.1   
Demographic Characteristics of 723 Adolescents Residing in 32 Missouri 
Division of Youth Services Residential Rehabilitation Facilities* 
Demographics N  (%) 
Age   
       11-12 9 (1.2) 
       13-14 120 (16.6) 
       15-16 472 (65.3) 
       17-18 114 (15.8) 
       19-20 8 (1.1) 
Gender    
       Male 629 (87.0) 
       Female 94 (13.0) 
Urbanicity of Family Residence     
       Urban 283 (39.1) 
       Suburban 100 (13.8) 
       Small Town 286 (39.6) 
       Rural 54 (7.5) 
Race    
       African American 238 (33.0) 
       White 400 (55.4) 
       Latino/Latina 28 (3.9) 
       Bi/Multi-Racial 56 (7.7) 
Current/Last Completed Grade    
       5th-6th  19 (2.6) 
       7th-8th  149 (20.7) 
       9th-10th  444 (61.6) 
       11th-12th  109 (15.1) 
*There were 2 missing values for the grade measure and 1 missing value for 
the race measure.   
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Table 2.2 
Bivariate Comparisons of Lifetime Prescription Drug Misusers (N = 314) and Nonusers (N = 
409) across Demographic, Health, Substance Use, Mental Health, Attitudinal, and 
Criminological Measures                                         
Variable  Lifetime PDMs Nonusers Results 
Demographic    
Gender  N (%)    
 Male 263 (83.8 %) 366 (89.5 %) χ2 (1) = 5.2, p < .05, ORa = 1.7 
(1.1 – 2.6)  
 Female 51 (16.2 %) 43 (10.5 %)  
Age  Mb (SD) 15.8 (1.1) 15.2 (1.3) t (718) = -6.8, p < .001, dc = 
.49 
Race  N (%)    
 African American 44 (14.0 %) 194 (47.5 %) χ2 (4) = 91.7, p < .001, OR = 
3.1 (2.3 – 4.3)* 
 White 222 (70.7 %) 178 (43.6 %)  
 Latino 15 (4.8 %) 13 (3.2 %)  
 Biracial 25 (8.0 %) 20 (4.9 %)  
 Other 8 (2.5 %) 3 (0.7 %)  
Urbanicity of Family Residence  N (%)   
 Urban 98 (31.2 %) 185 (45.2 %) χ2 (3) = 16.7, p < .01, OR = 
1.7 (1.2 – 2.3)** 
 Suburban 48 (15.3 %) 52 (12.7 %)  
 Small town 146 (46.5 %) 140 (34.2 %)  
 Rural/country 22 (7.0 %) 32 (7.8 %)  
Physical and Mental Health  N (%)   
History of:    
 Head injury with loss 
of consciousness 
69 (22.0 %) 63 (15.5 %) χ2 (1) = 5.1, p < .05, OR = 1.5 
(1.1 – 2.3) 
 Receipt of mental 
illness diagnosis 
189 (60.2 %) 181 (44.6 %) χ2 (1) = 17.3, p < .001, OR = 
1.9 (1.4 – 2.5) 
Substance Use  M (SD)    
 Lifetime number of 8.6 (3.0) 3.9 (2.3) t (566) = -22.9, p < .001, d = 
   62
drug classes used 1.76 
Massachusetts Youth Screening Inventory-2  M (SD)  
 Alcohol and Drug 
Problems  
5.4 (1.8) 2.9 (5.4) t (498) = -8.6, p < .001, d = 
.62 
 Suicidal Ideation  2.8 (2.5) 1.8 (2.2) t (631) = -5.7, p < .001, d = 
.42 
 Lifetime Trauma  3.3 (1.5) 2.7 (1.7) t (701) = -4.5, p < .001, d = 
.37 
Brief Symptom Inventory  M (SD)   
 Global Severity Index 50.4 (35.6) 38.7 (33.4) t (721) = -4.6, p < .001, d = 
.39 
 Somatization 4.0 (4.5) 3.3 (4.3) t (721) = -2.3, p < .05,  
d = .16 
 Obsessive Compulsive 8.0 (5.7) 5.5 (4.9) t (612) = -6.1, p < .001, d = 
.47  
 Depression 5.6 (5.4) 4.0 (4.7) t (622) = -4.2, p < .001, d = 
.32 
 Anxiety 5.2 (5.0) 3.7 (4.4) t (633) = -4.1, p < .001, d = 
.32 
 Hostility 6.7 (4.9) 5.5 (4.9) t (721) = -3.3, p < .01,  
d = .24 
 Phobic Anxiety 2.3 (3.4) 1.8 (3.0) t (721) = -2.1, p < .05,  
d = .16 
 Paranoid Ideation 7.0 (4.6) 5.7 (4.7) t (721) = -3.5, p < .01,  
d = .28 
 Psychoticism 4.4 (4.2) 3.1 (3.5) t (610) = -4.5, p < .001, d = 
.34 
Antisocial Process Screening Device M (SD)   
 APSD total 17.5 (5.3) 15.3 (5.5) t (720) = -5.4, p < .001, d = 
.41 
 Impulsivity 7.2 (1.9) 5.9 (2.2) t (720) = -8.0, p < .001, d = 
.63 
Psychopathic Personality Inventory  M (SD)   
 PPI Total 140.6 (14.6) 133.2 (12.7) t (619) = -7.2, p < .001, d = 
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.54 
 Social Potency 21.0 (4.1) 20.4 (4.2) t (721) = -2.1, p < .05,  
d = .14 
 Coldheartedness 15.6 (4.9) 14.9 (4.4) t (636) = -2.0, p < .05,  
d = .15 
 Carefree 
nonplanfulness 
15.2 (4.0) 13.5 (3.7) t (721) = -5.7, p < .001, d = 
.44 
 Fearlessness 18.2 (5.2) 16.2 (5.1) t (721) = -5.2, p < .001, d = 
.39 
 Blame externalization 18.8 (4.6) 17.8 (4.9) t (721) = -3.0, p < .01,  
d = .21 
 Impulsive 
nonconformity 
15.5 (4.5) 14.2 (3.8) t (609) = -4.1, p < .001, d = 
.31 
The Self-Report of Delinquency  M (SD)   
 SRD total 27.5 (18.4) 22.0 (18.2) t (721) = -4.0, p < .001, d = 
.30 
 Property crime 16.7 (11.7) 12.0 (11.5) t (721) = -5.4, p < .001, d = 
.41 
Victimization Index  M (SD)   
 Victimization Index 6.8 (5.8) 5.9 (6.0) t (721) = -2.0, p < .05,  
d = .15 
Onset of Criminal Offending and Contact with Police  M (SD) 
 Age at commission of 
first crime 
10.3 (2.7) 10.7 (3.0) t (719) = 2.0, p < .05, d = .14 
 Age at first contact 
with police 
10.8 (2.6) 11.2 (2.6) t (719) = 2.1, p < .05, d = .15 
a
 OR =  Unadjusted Odds Ratio with 95% Confidence Interval 
b M = Mean; SD = Standard Deviation 
c
 d = Cohen’s effect size for two independent groups computed using t-test values and associated 
degrees of freedom (cf., web.uccs.edu/lbecker/Psy590/es.htm for effect size calculator) 
*White vs. other 
**Small town vs. other 
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Table 2.3 
Multiple Logistic Regression Analysis (with simultaneous entry of variables) Identifying 
Correlates of Prescription Drug Misuse (N = 723) 
Variable b S.E. Wald p OR 
95.0 % CI 
(OR) 
Male vs. Female .28 .31 .80 .37 1.3 (.72-2.4) 
White vs. African American* 1.0 .30 12.4 .00 2.8 (1.6-5.0) 
Latino vs. African American .07 .57 .02 .90 1.1 (.36-3.2) 
Other races vs. African American 1.2 .43 7.4 .01 3.3 (1.4-7.6) 
Age (Years) .50 .10 24.0 .00 1.6 (1.3-2.0) 
Small town vs. Other levels of 
urbanization 
.41 .22 3.4 .07 1.5 (.97-2.3) 
History of mental illness .08 .22 .12 .73 1.1 (.70-1.7) 
Lifetime Inhalant user 1.0 .25 16.5 .00 2.8 (1.7-4.5) 
Cocaine/crack use .31 .28 1.2 .27 1.7 (.79-2.4) 
Lifetime Marijuana user 2.2 .56 15.5 .00 9.2 (3.0-27.6) 
Lifetime LSD user 1.5 .29 24.9 .00 4.3 (2.4-7.7) 
MAYSI-2a Substance-related 
problems 
.07 .05 1.9 .17 1.1 (.97-1.2) 
BSIb Global Severity Index .00 .00 .17 .68 1.0 (.99-1.0) 
PPIc Carefree Nonplanfulness .04 .03 1.6 .21 1.0 (.98-1.1) 
PPI Fearlessness -.03 .02 1.4 .24 .97 (.93-1.0) 
SRDd Property Crimes .02 .01 2.1 .15 1.0 (.99-1.0) 
APSDe Impulsivity Scale .13 .06 4.8 .03 1.1 (1.0-1.3) 
MAYSI-2 Suicidal ideation -.08 .06 2.0 .16 .93 (.83-1.0) 
MAYSI-2 Traumatic experiences .03 .08 .11 .74 1.0 (.89-1.2) 
a
 = Massachusetts Youth Screening Instrument; b = Brief Symptom Inventory; c = Psychopathic 
Personality Inventory; d = Self-Report of Delinquency; e = Antisocial Process Screening Device 
*Variables in bold are significant at the p < .05 level. 
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Table 2.4 
Multiple Logistic Regression Analysis (with simultaneous entry of variables Comparing Low- (N 
= 143) versus High- (N = 162) Frequency Prescription Drug Misusers 
Variable b S.E. Wald p OR 95.0 % CI 
(OR) 
White vs. African American .66 .41 2.6 .11 1.9 (.87-4.4) 
Latino vs. African American .82 .82 1.0 .32 2.3 (.46-11.3) 
Other vs. African American .01 .54 .00 .99 1.0 (.35-2.9) 
History of head injury .48 .35 1.9 .17 1.6 (.82-3.2) 
Age at 1st crime -.08 .05 2.5 .12 .92 (.84-1.0) 
Victimization index .05 .03 3.1 .08 1.1 (.99-1.1) 
MAYSI-2a Substance-related 
problems* 
.28 .08 11.3 .00 1.3 (1.1-1.6) 
MAYSI-2 Suicidal ideation .08 .06 1.9 .17 1.1 (.97-1.2) 
BSIb Somatization -.43 .31 1.9 .17 .65 (.35-1.2) 
BSI Anxiety .03 .04 .54 .46 1.0 (.95-1.1) 
PPIc Carefree nonplanfulness .01 .04 .06 .84 1.0 (.93-1.1) 
SRDd Violent offending -.02 .02 1.6 .21 .98 (.94-1.0) 
SRD Property crime .01 .01 .96 .33 1.0 (.99-1.0) 
APSDe Impulsivity .20 .08 5.5 .02 1.2 (1.0-1.4) 
a
 = Massachusetts Youth Screening Instrument; b = Brief Symptom Inventory; c = Psychopathic 
Personality Inventory; d = Self-Report of Delinquency; e = Antisocial Process Screening Device 
*Variables in bold are significant at the p < .05 level. 
 
   66
 
Table 3.1     
Description of Nine Indicator Variables Used in Latent Profile Analysis to Identify Latent Classes 
Variable Description Sample 
M* (SD) 
Reliability 
(alpha) 
1 Somatizationa Seven items assessing bodily dysfunction and 
discomfort (e.g., “pains in heart or chest”) 
4.1 (4.7) .77 
2 Depressiona Six items assessing dysphoric mood states (e.g., 
“feeling lonely”) 
5.9 (5.6) .82 
3 Anxietya Six items assessing nervousness, tension, and 
panic attacks (e.g., “feeling tense or keyed up”) 
5.4 (5.2) .80 
4 Phobic Anxietya Five items assessing persistent situational fear 
(e.g., “feeling nervous when you are left alone”) 
2.3 (3.5) .70 
5 Traumatic 
Experiencesb 
Four items assessing history of specific 
traumatic experiences (e.g., “ever seen someone 
severely injured or killed in person?”) 
3.3 (1.5) .69 
6 Alcohol/Drug 
Use Scaleb 
Eight items assessing substance-related 
problems (e.g., “ever been drunk or high at 
school?”) 
5.5 (1.7) .83 
7 Lifetime 
number of drug 
classes usedc   
“Yes or no” questions assessing use of each of 
15 categories of psychoactive substances 
9.0 (3.1)  
8 Self-Report of 
Delinquencyd   
Seventeen items assessing frequency of 
nonviolent and violent crime in past year (e.g., 
“stole marijuana”; “hit a parent”)  
28.6 
(18.6) 
.84 
9 Impulsivitye Five items assessing problems of impulse 
control (e.g., “engage in risky or dangerous 
activities”) 
7.2 (2.0) .67 
*M = Mean; SD = Standard Deviation  
a
 = Subscales of the Brief Symptom Inventory (BSI); item response options: 0 = not at all; 4 = 
extremely 
b 
= Massachusetts Youth Screening Instrument—2nd Version (MAYSI-2); item response options: 
“yes” or “no” 
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c 
= inhalants, heroin, opioids, cocaine/crack, speed, marijuana, hallucinogens, malt liquor, other 
alcohol, ecstasy (MDMA), GHB/GBL, cigarettes, cigars, oral tobacco, and PCP; range 0-15 
d 
= Self-Report of Delinquency; item response options: 0 (never) to 8 (2-3 times a day) 
e 
= Subscale of the Antisocial Process Screening Device; item response options: 0 = not at all 
true, 1 = sometimes true, 2 = definitely true 
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Table 3.2   
Fit Indices for Two, Three, and Four Class Latent Profile Models Identifying Subtypes of 
Adolescent Sedative/Anxiolytic Misusers (N = 247) 
Model BIC Entropy Lowest Class Probability L-M-R 
Two class 10617.07 .96 .97 .0006 
Three class 10552.47 .89 .94 .0024 
Four class 10543.73 .91 .92 .2868 
Note. BIC = Bayesian Information Criterion; L-M-R = Lo-Mendell-Rubin.   
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Table 3.3 
Differences among Three Latent Classes of Adolescent Sedative/Anxiolytic Misusers across Nine 
Latent Class Indicator Variables           
LPA Indicator Class 1* 
N = 146 
Class 2 
N = 28 
Class 3 
N = 73 
Results Significant 
Post-hoc 
tests** 
1 Somatizationa 1.7 (1.9) 13.6 (4.2) 5.4 (3.4) F(2,244) = 
233.0, p < 
.001 
1 < 2; 1 < 3; 3 
< 2 
2 Depressiona 2.9 (2.9) 15.2 (4.2) 8.4 (5.0) F(2,244) = 
144.0, p < 
.001 
1 < 2; 1 < 3; 3 
< 2 
3 Anxietya 2.1 (2.0) 15.8 (3.3) 7.9 (3.0) F(2,244) = 
403.4, p < 
.001 
1 < 2; 1 < 3; 3 
< 2 
4 Phobic Anxietya .82 (1.4) 9.3 (4.5) 2.7 (2.5) F(2,244) = 
159.1, p < 
.001 
1 < 2; 1 < 3; 3 
< 2 
5 Traumatic 
Experiencesb 
2.8 (1.5) 4.4 (.96) 4.0 (1.2) F(2,244) = 
31.3, p < .001 
1 < 2; 1 < 3 
6 Alcohol/Drug Use 
Scaleb 
4.9 (1.7) 6.6 (1.3) 6.3 (1.4) F(2,244) = 
23.8, p < .001 
1 < 2; 1 < 3 
 
7 Lifetime number of 
drug classes usedc   
8.0 (2.8)  11.0 (3.3) 10.2 
(2.8) 
F(2,244) = 
22.1, p < .001 
1 < 2; 1 < 3 
 
8 Self-Report of 
Delinquencyd   
22.2 
(15.3) 
45.3 
(19.3) 
34.9 
(18.3) 
F(2,244) = 
29.7, p < .001 
1 < 2; 1 < 3 
9 Impulsivitye 6.5 (1.9) 8.0 (1.7) 8.3 (1.6) F(2,244) = 
29.5, p < .001 
1 < 2; 1 < 3 
*Entries in each column = Mean (Standard Deviation). **Tamhane post-hoc tests were conducted 
for all ANOVAs.  
a
 = Subscales of the Brief Symptom Inventory (BSI) (Derogatis, 1993) 
b 
= Massachusetts Youth Screening Instrument—2nd Version (MAYSI-2) (Grisso & Barnum, 
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2000) 
c 
= inhalants, heroin, opioids, cocaine/crack, speed, marijuana, hallucinogens, malt liquor, other 
alcohol, ecstasy (MDMA), GHB/GBL, cigarettes, cigars, oral tobacco, and PCP; range 0-15 
(Howard et al., 2008) 
d 
= Self-Report of Delinquency (Elliott et al., 1989) 
e 
= Subscale of the Antisocial Process Screening Device (Vitacco et al., 2003) 
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Table 3.4 
Comparisons of Three Latent Classes of Adolescent Sedative/Anxiolytic Misusers across 
Demographic, Health, Substance Use, Mental Health, Attitudinal, and Criminological Measures.          
Variable  Class 1 
N = 146 
Class 2 
N = 28 
Class 3 
N = 73 
Results Significant 
Post-hoc tests 
Demographic      
Gender  N (%)      
 Male 126 (86.3%) 21 (75.0%) 60 (82.2%) χ2 (2) = 2.4, n.s.   
 Female 20 (13.7%) 7 (25.0%) 13 (17.8%)   
Age  M (SD) 15.8 (1.2) 15.9 (.94) 15.9 (.90) F (2, 244) = .27, 
n.s. 
 
Race*  N (%)      
 African 
American 
24 (16.4%) 4 (14.3%) 6 (8.2%)   
 White 106 (72.6%) 17 (60.7%) 50 (68.5%)   
 Latino 2 (1.4%) 5 (17.9%) 6 (8.2%)   
 Biracial 10 (6.8%) 1 (3.6%) 9 (12.3%)   
 Other 4 (2.7%) 1 (3.6%) 2 (2.7%)   
Urbanicity of Family Residence  N (%)   
 Urban 38 (26.0%) 13 (46.4%) 26 (35.6%) χ2 (6) = 6.7, n.s.  
 Suburban 21 (14.4%) 4 (14.3%) 12 (16.4%)   
 Small town 74 (50.7%) 10 (35.7%) 29 (39.7%)   
 Rural/country 13 (8.9%) 1 (3.6%) 6 (8.2%)   
Physical and Mental Health  N (%)   
History of:     
 Head injury with  
unconsciousness 
22 
(15.2%) 
16 (57.1%) 17 (30.9%) χ2 (2) = 23.9, p 
< .001 
1 < 2; 3 < 2 
 Birth 
complications 
6 (4.1%) 2 (10.5%) 11 (15.1%) χ2 (2) = 8.2, p < 
.05 
1 < 3 
 Receipt of 
mental illness 
diagnosis 
72 
(49.3%) 
20 (71.4%) 54 (74.0%) χ2 (2) = 14.2, p 
< .01 
1 < 3 
   72
 Hearing voices 16 
(11.0%) 
9 (32.1%) 15 (20.5%) χ2 (2) = 9.2, p < 
.05 
1 < 2 
Mental Health     
Massachusetts Youth Screening Inventory-2  M (SD)   
 Suicidal Ideation  2.1 (2.3) 4.9 (1.7) 3.8 (2.3) F (2, 244) = 
25.3, p < .001 
1 < 2; 1 < 3; 3 
< 2 
Brief Symptom Inventory  M 
(SD) 
    
 Obsessive 
Compulsive 
4.8 (3.7) 17.5 (3.8) 11.1 (4.5) F (2, 244) = 
150.4, p < .001 
1 < 2; 1 < 3; 3 
< 2 
 Interpersonal 
Sensitivity 
1.5 (2.1) 8.1 (3.6) 4.3 (3.4) F (2, 244) = 
82.5, p < .001 
1 < 2; 1 < 3; 3 
< 2 
 Hostility 4.4 (3.7) 12.3 (4.6) 9.5 (4.7) F (2, 244) = 
66.4, p < .001 
1 < 2; 1 < 3; 3 
< 2 
 Paranoid 
Ideation 
4.7 (3.2) 13.4 (3.7) 9.3 (3.9) F (2, 244) = 
96.0, p < .001 
1 < 2; 1 < 3; 3 
< 2 
 Psychoticism 2.3 (2.9) 10.9 (3.3) 6.5 (3.8) F (2, 244) = 
102.4, p < .001 
1 < 2; 1 < 3; 3 
< 2 
Substance Use Frequency  
Frequency of:  M (SD)  
 Sedative/ 
anxiolytic use 
2.7 (1.7) 4.0 (2.0)  3.8 (2.1) F (2, 244) = 
12.4, p < .001 
1 < 2; 1 < 3 
 Opioid use 2.3 (1.2) 2.6 (1.3) 2.9 (1.0) F (2, 170) = 4.9, 
p < .01 
1 < 3 
 Cocaine use 2.1 (1.2) 3.1 (1.1) 2.7 (1.2) F (2, 113) = 6.6, 
p < .01 
1 < 2; 1 < 3 
 Marijuana use 3.8 (.54) 4.0 (.19) 4.0 (.20) F (2, 243) = 4.4, 
p < .05 
1 < 2; 1 < 3 
 
 LSD use 1.9 (1.1) 2.8 (.95) 2.2 (1.0) F (2, 118) = 4.8, 
p < .01 
1 < 2 
 Malt liquor use 2.9 (1.0) 3.2 (1.0) 3.3 (.81) F (2, 171) = 4.1, 
p < .05 
1 < 3 
 Alcohol use 3.2 (.92) 3.7 (.68) 3.5 (.78) F (2, 237) = 5.7, 
p < .01 
1 < 2; 1 < 3 
   73
Personality   
Antisocial Process Screening Device M (SD)   
 Narcissism 1.7 (1.8) 2.5 (1.0) 2.5 (1.3) F (2, 244) = 
12.5, p < .001 
1 < 2; 1 < 3 
Psychopathic Personality Inventory  M (SD)   
 PPI Total Score 139.1 
(13.7) 
144.8 
(19.3) 
144.5 
(14.4) 
F (2, 244) = 4.2, 
p < .01 
1 < 3 
 Machiavellian 
Egocentricity 
16.1 (4.2) 19.5 (3.8) 18.8 (3.7) F (2, 244) = 
15.7, p < .001 
1 < 2; 1 < 3 
 Social Potency 22.0 (3.7) 18.4 (4.6) 20.9 (4.1) F (2, 244) = 
10.2, p < .001 
2 < 1; 2 < 3 
 Coldheartedness 16.9 (4.8) 13.1 (5.2) 14.8 (4.5) F (2, 244) = 
10.3, p < .001 
2 < 1; 3 < 1 
 Carefree 
Nonplanfulness 
14.2 (3.8) 17.8 (4.5) 16.4 (3.3) F (2, 244) = 
16.3, p < .001 
1 < 2; 1 < 3 
 Fearlessness 17.9 (5.4) 19.5 (5.1) 19.2 (5.2) F (2, 244) = 
12.5, n.s. 
 
 Blame 
Externalization 
17.4 (4.5) 22.4 (3.7) 20.6 (4.2) F (2, 244) = 
23.5, p < .001 
1 < 2; 1 < 3 
 Impulsive 
Nonconformity 
14.4 (4.2) 18.8 (4.6) 16.8 (4.3) F (2, 244) = 
15.8, p < .001 
1 < 2; 1 < 3 
 Stress Immunity 20.3 (4.0) 15.6 (3.9) 17.1 (3.8) F (2, 244) = 
27.2, p < .001 
2 < 1; 3 < 1 
Criminological     
Victimization Index  M (SD)     
 Victimization 
Index 
5.3 (4.8) 11.5 (7.0)  9.3 (6.6) F (2, 244) = 
21.6, p < .001 
1 < 2; 1 < 3 
Note. M = Mean; SD = Standard Deviation. Some variables may not total 100.0% due to 
rounding error. Due to space limitations, the following non-significant group comparisons were 
not reported: frequency of heroin, ecstasy, and PCP use, and age of onset of criminal offending 
and contact with police. Tamhane post-hoc tests were conducted for all ANOVAs. Significant 
chi-square tests were subsequently evaluated using z-tests comparing class proportions (p values 
were adjusted using Bonferroni method for multiple comparisons). *Due to small cell sizes, chi-
square tests were not conducted on this variable.  
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